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ABSTRACT 
OBSERVING THE MOLECULAR BASIS OF THIN FILAMENT ACTIVATION 
WITH A THREE BEAD LASER TRAP ASSAY 
 
FEBRUARY 2018 
THOMAS J. LONGYEAR, B.S., UNIVERSITY OF ALABAMA HUNTSVILLE 
M.S., UNIVERSITY OF MASSACHUSETTS 
Ph.D., UNIVERSITY OF MASSACHUSETTS 
Directed by: Professor Edward P. Debold 
 Muscle contracts after calcium (Ca++) is released into the muscle cell, resulting 
from a cascade of events which result in myosin, the molecular motor of muscle, to 
produce force and motion. Myosin cyclically binds to a regulated thin filament, using the 
chemical energy of ATP to produce force and motion. Perturbations in muscle, such as a 
build-up of metabolic by-products or point mutations in key contractile proteins, can 
inhibit these functions in both skeletal and cardiac muscle either acutely or chronically. 
Despite the many years we have studied skeletal and cardiac muscle, we still do not have 
a clear picture of the effect of these perturbations at the molecular level. Indeed, we do 
not even have a clear picture of how muscle is activated at the molecular level. Such an 
understanding would provide a foundation for future work, and aid our understanding of 
perturbations such as muscle fatigue or point mutations. Recent advances in biophysical 
techniques have allowed us to directly observe both single myosin and small ensembles 
of myosin interacting with an actin filament. We build off this previous work by 
examining 1) a single myosin molecule interacting with a regulated actin thin filament, 
and 2) small ensembles of myosin working together to pull on a regulated thin filament. 
We set out to directly determine how Ca++ and myosin activate the thin filament and thus 
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muscle. Our approach to directly observe these molecular phenomena across 
physiological Ca++ levels as well as high ATP concentrations is novel. The first goal of 
this work was to examine how 1) a single myosin interacts with a regulated thin filament 
and 2) how a small ensemble of myosins work together to generate force and motion in a 
Ca++ dependent manner as they interact with a regulated thin filament. The findings build 
on previous work using similar techniques, but are rich in data and provide a more 
physiological viewpoint. The second goal of this work was to examine a particular 
mutation that leads to hypertrophic cardiomyopathy. The current evidence suggests that 
this mutation alters both thin filament dynamics and myosin kinetics. This mutation was 
thus chosen not only to add to our understanding of this particular mutation in hopes of 
developing a therapeutic, but also to provide insight into the role of thin filament 
activation and myosin dynamics in hopes of better understanding muscle contraction 
overall. With our experiments, supplemented with a mathematical model, we have de-
convolved the role of Ca++ and myosin in thin filament activation, and developed a model 
of muscle activation from the single molecule up to the scale of a cell.  
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CHAPTER 1 
INTRODUCTION 
  For over 100 years, the machinery and mechanism for muscle contraction has 
been studied. Despite this long history, there are many unresolved questions, particularly 
on the molecular level. How a single myosin molecule interacts with a regulated actin 
filament (also called a ‘regulated thin filament’) is unknown. Further, how a small 
ensemble of myosins work together to bind to a regulated actin filament to produce force 
and motion is not clear. Considering in vivo muscle is structured so that a small ensemble 
of myosins interact with a regulated thin filament, experiments that can directly observe 
these conditions would be extremely valuable. We know that during a muscle 
contraction, calcium (Ca++) is released into the muscle cell, leading to partial activation of 
the regulated thin filament. Myosin can then strongly bind to the thin filament, leading to 
complete activation. However, the details of this thin filament activation are unclear. The 
relative contribution of Ca++ and myosin to thin filament activation is of particular 
interest if we are to better understand the molecular processes of muscle. The complete 
understanding of thin filament activation is applicable to many conditions, including 
submaximal Ca++, muscle fatigue, or point mutations.  
 Muscle fatigue is defined as a transient decrease in the generation of force and/or 
velocity in response to exercise (32, 38). Muscle fatigue has fundamental implications for 
exercise physiology, but is also a debilitating symptom of heart failure, which limits 
physical activity and negatively impacts the patient’s prognosis (43, 99). Despite the 
importance and history of muscle fatigue, the etiology of fatigue is not fully understood. 
A major hurdle to our understanding is our inability to observe molecular phenomena that 
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cause muscle fatigue. In fact, the inability to observe molecular phenomena has hindered 
our understanding of the molecular machinery of muscle even under normal conditions, 
let alone fatigue like conditions. Before further examining the etiology of fatigue, a better 
understand how the molecular machinery of muscle works under normal conditions 
would be of great benefit. A major goal of this dissertation was to provide insight into the 
molecular details of muscle contraction, and lay a foundation for future work the examine 
the molecular details of muscle fatigue. 
 Macroscale experiments that include human or animal participants, whole muscle, 
and even single muscle fibers have been informative, but are unable to provide 
information on the molecular details of muscle function, and thus muscle fatigue. Despite 
a long history of study, only in the last 20 years have we been able to directly examine 
muscle structure and function at the single molecule level (37). With new techniques now 
in hand, such as the laser trap assay, a better understanding of muscle function on the 
molecular level can be obtained. We can now examine the role of myosin and the 
regulatory proteins during muscle activation.  
What follows is a description of our current understanding of the molecular 
machinery of muscle, including myosin and the regulated thin filament. In addition, we 
will discuss how this machinery and its function leads to macroscopic observations, and 
how these observations change with perturbations such as fatigue or mutations in key 
contractile proteins. Finally, we will discuss experiments that can be performed that 
would address our questions about myosin’s function and thin filament activation under 
normal conditions, as well as under conditions with specific perturbations.   
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At the molecular level, muscle contraction is driven by myosin, which is the 
molecular motor in muscle. Myosin is an ATPase, converting the chemical energy of 
ATP into mechanical work. Within a muscle fiber, myosin molecules are organized into a 
thick filaments and are able to bind to the thin filament, composed of actin. The myosin 
molecules cyclically bind to the thin filament, producing force and motion with each 
binding event. This cycle starts when myosin binds to actin and generates a 
“powerstroke” of approximately 10 nm (figure 1.1, step 1) (25, 37, 119). Myosin then 
releases one of the ATP hydrolysis products, inorganic phosphate (Pi), into the cytosol, 
and this release is in close temporal proximity to this powerstroke (5, 20, 33). Some 
hypothesize that myosin then goes through an isomerization (26, 106), where there is 
some slight structural change without a biochemical change (step 2) (21, 26, 106). 
Myosin then releases ADP into the cytosol (step 3) and an ATP molecule will then bind 
to myosin, causing dissociation of myosin and actin (step 4). Myosin will hydrolyze the 
ATP (step 5) and the cycle repeats; this cycle is known as the “crossbridge cycle”. Each 
cycle generates an approximate 10 nm displacement. Thus, the faster myosin can move 
Figure 1.1 Model of the crossbridge cycle. During skeletal muscle contraction, myosin strongly binds to actin, 
releases Pi, and generates a powerstroke (step 1). Myosin then goes through an isomerization (with no 
biochemical change, step 2) and then releases ADP (step 3). ATP then binds to myosin, causing actomyosin 
dissociation (step 4). Myosin then hydrolyzes ATP (step 5) and the cycle repeats. It is possible that acidosis slows 
each of these steps. 
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through the cycle, the more displacement will be generated in a given time, and therefore 
more velocity is generated. Because myosin is the molecular motor of muscle, the speed 
at which the crossbridge cycle occurs is the direct cause of muscle contraction velocity. 
In addition, the force muscle produces is the product of the number of myosin’s attached 
to the regulated thin filament and how much force each myosin produces.  
In order to fully understand the crossbridge cycle, we need to know how the 
myosins interact with regulated actin, as is the case in vivo. Our understanding should 
include not only rested conditions, but also conditions observed during fatigue in vivo. 
These fatigue conditions can alter myosin’s function, resulting in changes in thin filament 
activation. Previous work has shown that specific changes within the muscle that occur 
during fatigue (13, 23, 64) lead to a reduction in force and velocity, most likely by 
altering myosin’s crossbridge cycle. For example, reducing the pH from 7.0 to 6.2 led to 
a decrease in force by 3-14%, velocity by 10-30%, and power by 34% (63, 67, 88). 
However, which step(s) of the crossbridge cycle are affected by acidosis is unclear. ATP 
hydrolysis, myosin’s strong binding to the thin filament, and/or ADP release may be 
altered; however, this has not been directly observed (25, 82, 100, 105). In addition, there 
is evidence that acidosis alters myosin’s force generating capacity (82). Previous work in 
single muscle fibers has suggested that a decrease in pH from 7.0 to 6.2 leads to a 
decrease in stiffness by approximately 25% (82). However, these data were collected 
with single muscle fibers (which contain billions of myosin molecules) at below 
physiological temperatures (10 or 15° C). Such experiments with billions of myosin 
molecules don’t provide direct insight into the effects of acidosis on myosin’s function, 
and temperature has been shown to have a significant impact on myosin’s on-rate as well 
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as the effect of acidosis (95, 96, 137). Experiments with a single myosin molecule at 
near-physiological temperatures (30° C) can be performed with a laser trap assay to 
address this. This assay can be used to not only understand the molecular details of 
muscle under normal conditions, but also under fatigue-like conditions. Experiments 
exploring fatigue can be performed in future work once we have a better picture of how 
myosin works under normal conditions.  
Clearly, myosin plays a key role in muscle’s function, and specific perturbations 
that alter muscle output are due to direct effects on myosin. Additional key players 
include the regulatory proteins, troponin (Tn) and tropomyosin (Tm). The interaction 
between myosin and actin is regulated by Ca++ binding to troponin. This Ca++ binding 
will lead to a chain of events, involving structural and dynamic changes in troponin, 
tropomyosin, myosin and actin, eventually leading to muscle contraction. Troponin 
consists of three subunits: the Ca++ binding subunit, troponin C (TnC), the inhibitory 
subunit, which is responsible for inhibiting contraction during muscle relaxation, troponin 
I (TnI), and the tropomyosin binding subunit, troponin T (TnT). Ca++ binding to TnC 
leads to slight structural changes the TnC structure, where a hydrophobic patch is 
exposed on the N-terminus. The C-terminus of TnI, which plays the crucial role of 
binding to actin and keeping the regulatory proteins in place during relaxation and 
preventing actomyosin binding, will relieve itself of this duty by releasing actin and 
binding to the exposed hydrophobic patch. With only minor forces keeping tropomyosin 
on actin, tropomyosin is now free to slide over the actin surface, which reveals myosin 
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binding sites on actin (see figure 1.2). 
 
Figure 1.2. Cartoon of TnI at low and high calcium. a) With no calcium bound to troponin C, troponin I stays 
bound to actin, keeping tropomyosin in the blocked state. b) Upon calcium binding, troponin I detaches from 
actin and binds to troponin C, allowing tropomyosin to move freely about the actin surface.  
The function of regulatory proteins is crucial; minor changes in Ca++ 
concentrations can lead to large changes in troponin and tropomyosin’s position on actin, 
and thus can lead to large changes in muscle force. Therefore, perturbations that alter 
Ca++ binding to troponin or that alter troponin’s function can have significant 
implications. For example, mutations in troponin can lead to cardiomyopathies by 
presumably altering these Ca++-dependent motions. In addition, during muscle fatigue, 
Ca++ levels decrease (71) and positively charged hydrogen ions may compete with Ca++ 
for binding to troponin (88, 93). Both mechanisms can lead to a drastic reduction in 
muscle output. The precise molecular mechanisms are unknown.  
Prior to Ca++ release, tropomyosin is in the “blocked” state, where tropomyosin 
physically blocks actomyosin binding. Upon Ca++ binding to troponin, tropomyosin is 
moved into the “closed” state, where tropomyosin’s position fluctuates across actin’s 
surface and binding sites are transiently available to myosin. Once in the closed state, 
tropomyosin is pushed into the “open” state upon myosin binding. This premise, known 
as the three state model, is strongly supported by biochemical experiments (72, 81, 118), 
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in vitro experiments (29, 62), protein structures (19, 98, 108, 122, 125), and mathematical 
models (126). Thus, both Ca++ binding to troponin and myosin binding to actin are 
critical to thin filament activation, where thin filament activation is a measure of how 
available the myosin binding sites on actin are. As stated earlier, perturbations such as 
troponin mutations or fatigue-like conditions can alter muscle output. In the three-state 
model, acidosis may block Ca++ binding to troponin, potentially keeping tropomyosin in 
the blocked state. This would result in less actomyosin binding and thus less muscle 
output. This reduced binding not only affects each myosin, but can also affect 
neighboring myosin due to the cooperative nature of myosin binding. 
A key component of thin 
filament activation is the cooperative 
binding of myosin molecules to the 
regulated thin filament. Once one 
myosin strongly binds to actin and 
pushes tropomyosin into the open 
state, other myosin molecules can 
more easily bind to actin. Cooperativity 
can be seen graphically in the pCa-force 
and pCa-velocity relationships, an example of which is shown in figure 1.3. In this figure, 
the x-axis is pCa, which represents the negative log of Ca++ (pCa 4 is high Ca++, pCa 7 is 
relatively low Ca++). Force output is very low at low Ca++ levels, but as Ca++ increases, a 
drastic increase in force occurs. As more Ca++ is present, the regulatory proteins can more 
readily move out of the blocked state, and myosin can bind. Clearly, both Ca++ and 
pCa
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Figure 1.3. Typical force-pCa relationship. A muscle 
fiber’s force generating capacity is dependent on the Ca++ 
concentration. The curve is sigmoidal, and the curve is 
steep, suggesting high cooperativity. 
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myosin play a crucial role in thin filament activation, but is one more important than the 
other? The precise role of each of these players in thin filament activation and 
cooperativity are not completely understood. Understanding these roles is significant to 
both skeletal and cardiac muscle because during muscle activation, the physiological 
Ca++ concentration usually lies within the steep portion of the pCa-force relationship. 
Small changes in Ca++ can lead to large changes in myosin binding and subsequent force 
production. Further, how activation and cooperativity are altered by acidosis and other 
metabolites produced during fatigue is unclear, though evidence exists that acidosis 
affects these parameters (22, 24, 88, 93, 133, 135). Therefore, understanding the roles of 
myosin and Ca++ under normal conditions is imperative so that we can better understand 
the molecular details of fatigue in subsequent experiments. A key goal of this 
dissertation was to determine the role of myosin and Ca++ in thin filament 
activation. This was achieved with the state-or-the-art laser trap assay that allows 
direct observation of single myosin and myosin ensembles generating force. By 
directly observing the binding of a single myosin or an ensemble of myosin to a 
regulated thin filament while controlling the level of Ca++, we de-convolved the role 
of both myosin and Ca++ in activation. 
With a better understanding of how myosin and the regulatory proteins lead to 
thin filament activation, we will be able to understand how specific perturbations affect 
thin filament activation, as well as cooperativity and the resulting pCa-force relationship. 
For example, mutant troponins can lead to changes in these measures. The mutations that 
lead to muscle dysfunction are typically found in key regions of troponin. One key region 
is the Ca++ binding pocket. Obviously, a mutation here could alter Ca++ binding and 
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subsequent thin filament activation. Another key region is the inhibitory region, which 
binds to actin and prevents tropomyosin from moving and exposing actomyosin binding 
sites. A mutation in this region could allow tropomyosin to expose actomyosin binding 
sites in the absence of Ca++. One example of this is a mutation called R146G. This 
mutation is associated with hypertrophic cardiomyopathy and seems to allow actomyosin 
binding in the absence of Ca++ (34, 70, 114, 129). Unfortunately, the precise mechanism 
R146G’s action is unknown. More precise techniques are required to understand its effect 
on thin filament activation and potentially help the patients with this mutation. A second 
key goal of this dissertation was to examine how R146G has its effects on myosin 
kinetics and regulated thin filament activation. 
To obtain a better understanding of thin filament activation, experiments on the 
molecular level that can examine a single myosin’s ability to interact with the thin 
filament are crucial. Further, experiments that mimic physiological conditions by 
examining how a small ensemble of myosin work together to activate the thin filament 
Figure 1.4. Cartoon of the 3-bead assay. Myosin is randomly oriented on the microscope slide surface, 
occasionally located on a pedestal bead. A bead-filament-bead assembly, trapped by laser light, is put in close 
vicinity to the pedestal so single molecule interactions can be observed and measured. Figure courtesy of Mike 
Woodward. 
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could bridge the gap between our current understanding of single myosin molecule 
kinetics and single muscle fiber experiments. This can be achieved with the 3-bead laser 
trap assay, where two beads, which are trapped by laser light, hold a single actin filament 
taught, while a single myosin sitting on a pedestal bead binds to the actin filament (figure 
1.4). This technique, with millisecond time and nanometer spatial resolution, allows us to 
directly observe a single molecule interaction, giving us displacement, duration of 
attachment, and binding frequency of individual actomyosin interactions. This technique 
can also be used to examine how multiple myosins pull on a single actin filament 
cooperatively to generate force.  
 In addition to collecting novel information on thin filament activation, a key 
outcome from future work is to be able to use our knowledge of the molecular details to 
understand how specific perturbations lead to dysfunction. In addition to setting the 
foundation for examining fatigue, the knowledge gained in this work can set the 
foundation for examining mutations that cause disease. Our understanding of the 
molecular details of normal, wildtype proteins can help us construct models for 
mutations, especially those that cause cardiomyopathies.  
The expectation for this dissertation was to create a better understanding of 
muscle on the molecular level and begin applying that knowledge to specific 
perturbations. One perturbation that we have gained interest in is the R146G mutation in 
TnI. This mutation was chosen because it is known to cause cardiomyopathy (60, 65), 
because of its crucial location in TnI (36, 113, 115), and because the evidence is 
inconclusive. Though this mutation has been studied previously, there is still little 
consensus on its effect. For example, some have shown that the R146G negatively affects 
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force, while others have seen no effect (70, 114, 129, 132). More puzzling is the effect 
this mutation has on the Ca++ dependent production of force and velocity: previous data 
has shown that force and velocity are reduced at high Ca++ compared to wildtype Tn, but 
force and velocity are increased at low Ca++ (12, 60, 69, 70, 114, 129, 132). The 
molecular mechanisms that lead to these odd phenomena are not well understood. 
Experiments that examine both thin filament activation as well as myosin kinetics in the 
presence of this mutation are necessary to gain a full mechanistic understanding of this 
mutation. By manipulating conditions in an in vitro environment, we can gain novel 
insight into how this mutation causes dysfunction. Future work can then use our 
understanding of the molecular details of muscle contraction to ameliorate the negative 
effects of cardiomyopathies.   
 Overall, the goal of this dissertation was to use state-of-the-art single molecule 
techniques to better understand regulated thin filament activation. In recent years, many 
experiments have been performed with either single muscle fibers which contain billions 
of myosin or with single myosin molecules interacting with an unregulated thin filament. 
The current dissertation bridges the gap between these two methods by incorporating 
regulated thin filaments with single, small ensemble, and large ensembles of myosin. 
This work lays the foundation for future work examining perturbations that cause muscle 
fatigue. Another key goal was to better understand how a cardiomyopathy mutation in 
troponin leads to functional changes. These outcomes give us a better understanding of 
the molecular details of muscle contraction and help us apply our knowledge to attenuate 
the negative effects of cardiomyopathy mutations.  
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Hypotheses 
Hypothesis 1: Both Ca++ and myosin play crucial roles in thin filament activation.  
A) During single molecule experiments in the 3-bead assay, myosin’s binding to 
the regulated thin filament will be Ca++ dependent. 
a. The frequency of binding will be reduced as Ca++ levels are reduced. 
b. The displacement generated upon myosin binding will not be Ca++ 
dependent. 
B) During experiments with small ensembles of myosin in the 3-bead assay, the 
force generated will be Ca++ dependent and will show elements of 
cooperativity. 
a. Many events will be recorded with various forces, and the distributions 
will shift as Ca++ is decreased where force and event frequency will 
decrease. 
b. The distributions will show cooperativity by containing many events 
with high force. This cooperative action will be observed by direct 
observation of moderate forces even at low to moderate calcium (pCa 
6-7).  
i. This suggests that once one myosin binds, many others bind as 
well, leading to a distribution of forces with more high forces 
than low forces. 
C) During experiments with large ensembles of myosin in an in vitro motility 
assay, the velocity generated will be dependent on both ATP, which directly 
influences the number of myosin bound, and Ca++ concentrations. 
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a. Under conditions of low ATP and low Ca++, velocity will be observed, 
suggesting that myosin in rigor can activate the thin filament in the 
absence of Ca++. 
b. This suggests that both myosin and Ca++ play a role in thin filament 
activation. Under low ATP and low Ca++, activation is driven by 
myosins that are strongly bound in a rigor state, while high ATP and 
high Ca++ leads to contributions from both strongly bound myosin and 
Ca++. 
Hypothesis 2: The R146G mutation in troponin I disrupts the normal pCa-velocity 
relationship by altering multiple steps of the crossbridge cycle.    
A) During pCa-velocity experiments, the R146G mutation will lead to enhanced 
velocity under low Ca++ conditions but reduced velocity under high Ca++ 
conditions. 
a. This will lead to a reduced Hill coefficient, which suggests a reduction in 
cooperativity.  
b. The mutation will also cause an increase in the Ca++ sensitivity, as 
determined by the pCa50. 
B) During duty cycle experiments, the R146G mutation will cause an increase in the 
duty cycle. 
a. This will suggest that the R146G affects myosin kinetics, either increasing 
the rate of the strong binding step or slowing the rate of ADP release. The 
most likely steps altered are strong binding and ADP release.  
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C) During ATP-velocity experiments, the R146 mutation will slow velocity at any 
given ATP level, suggesting that ADP release is slowed in the presence of the 
R146G mutation.  
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CHAPTER 2 
 
LITERATURE REVIEW 
The Crossbridge Cycle 
Myosin uses energy from ATP hydrolysis to cyclically bind to actin and produce 
force and motion. This cyclical binding is commonly referred to as the crossbridge cycle. 
When a muscle is in a resting state, most myosin are in a ‘cocked’ state, with the myosin 
head ready to bind to actin and release its hydrolysis products, ADP and Pi. Upon muscle 
activation, Ca++ binds to troponin and the regulatory proteins allow myosin to strongly 
bind to actin. When this occurs, myosin releases Pi, generates force, and produces an 
approximate 10 nm displacement of actin, all in a matter of a few milliseconds (37). 
Myosin continues to produce force as long as it is strongly bound to actin, the duration of 
which is referred to as “time-on” (ton). During this strongly bound state, there is evidence 
that myosin isomerizes with ADP still bound (26, 106). Myosin then releases ADP and 
binds an ATP molecule, which causes dissociation of myosin and actin. From here, 
myosin can hydrolyze this ATP molecule, which re-cocks the myosin head, and the 
crossbridge cycle can begin again. 
The crossbridge cycle affects force and velocity  
To discuss myosin’s function, we must discuss what limits myosin’s function and 
its subsequent force and velocity production. The force generated by a muscle fiber is the 
product of the number of myosin molecules in that fiber strongly bound to actin 
multiplied by the force per myosin molecule (58, 59). Therefore, the longer myosin stays 
attached to actin (i.e., ton) relative to the time off of actin (toff), the more myosin 
molecules will be bound at any given time, increasing the force produced. Based on this, 
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an increased rate in attachment and a decreased rate of detachment would lead to more 
myosin bound and thus more force. Experiments performed in the laser trap assay have 
shown that specific biochemical steps are force dependent, such as ADP release (121). 
The more force a given myosin is producing, the longer myosin would take to release 
ADP. This provides a mechanochemical explanation for prolonged attachment and high 
force production. Velocity, on the other hand, is assumed to be limited by detachment 
(59, 128), that is, velocity is equal to the displacement generated by myosin divided by 
the time myosin spends strongly bound to actin (59). The faster myosin can detach, the 
faster a muscle will contract. This model agrees well with data suggesting that ADP 
release, an event that occurs with myosin bound to actin, is the biochemical step that 
limits velocity (91). Simply, force is dependent on myosin being bound to the actin 
filament, while velocity is dependent on the rate of detachment from the actin filament. 
This juxtaposition is the basis for the inverse relationship of force and velocity. This 
relationship was shown in seminal work by A.V. Hill (55) in whole muscle. Evidence 
that myosin is responsible for this action was demonstrated with the laser trap assay, 
where a small ensemble of myosin was able to reproduce the force-velocity relationship 
(27). 
Effect of metabolites on the crossbridge cycle 
Changes to the concentration of specific metabolites can affect the kinetics of the 
crossbridge cycle. Some of these metabolites have been suspects for muscle fatigue. This 
includes ATP, inorganic phosphate (Pi), and acidosis. 
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ATP 
A reduction in ATP was once considered a culprit of fatigue. As ATP 
concentrations are reduced, the rigor lifetime of a myosin crossbridge increases, which 
would slow velocity. Current estimates put ATP levels around 5 mM in fresh muscle, and 
as low as 1 mM in severely fatigued muscle (2). However, 1 mM is more than sufficient. 
The concentration of ATP that leads to half-maximal binding of myosin, also known as 
the Km, is approximately 5 uM. Therefore, a decrease to 1 mM would still allow 
sufficient ATP-myosin binding, and would not have a significant effect on myosin’s 
function.   
Inorganic Phosphate (Pi) 
 Another major culprit of muscle fatigue is inorganic phosphate (Pi). Even small 
amounts of Pi (5 mM) can negatively impact force (18, 20, 28), though some have 
postulated that concentrations can reach as high as 30 mM during fatigue (13, 23, 134). Pi 
release and force generation have been examined extensively, as Pi release is closely 
associated with force generation and are hard to tease apart. One current hypothesis is 
that Pi rebinds to actomyosin, inducing dissociation between actin and myosin and thus 
limiting force production. This hypothesis was validated with single molecule 
experiments in the laser trap assay recently (28).  
Acidosis 
Finally, acidosis is likely to be the most studied culprit for muscle fatigue. 
Acidosis has been proposed to affect more than one step of the crossbridge cycle. 
Surprisingly, there is relatively little evidence showing which kinetic step is altered. 
Recent work has shown force to decline 10-18% and velocity to decline by up to 70% 
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(63, 67, 88). For this to occur, specific steps of the crossbridge cycle must be slowed. 
Based on the steps that limit force and velocity, three steps are likely slowed: 1) the 
strong binding, force-generating step, 2) ADP release, and 3) ATP hydrolysis.  
 The first potential step acidosis may alter is myosin’s strong binding to actin. 
Insightful release and re-stretch experiments performed in single muscle fibers suggested 
that strong binding was slowed (83). In fact, later work suggested that the acidosis-
induced changes observed in both force and velocity could be explained by this one 
step’s rate (105). Additional work comparing the change in force and ATPase as a 
function of pH also suggested that the rate of attachment is slowed as pH is reduced 
(100). One technique that could address the rate of strong binding is the single molecule 
laser trap assay. In this assay, individual binding events between myosin and the thin 
filament can be directly observed. The rate of strong binding can be determined by 
recording the number of events over time and determining the binding frequency. This 
binding frequency can be measured in the presence or absence of acidosis and the effect 
of acidosis on strong binding can be observed and quantified.  
The second kinetic step that could be altered by acidosis is ADP release. There is 
strong evidence that ADP release is slowed by acidosis, where reducing the pH from 7.4 
to 6.4 increased the lifetime of a single actomyosin bond 3-fold (25). This was directly 
observed in the laser trap assay, where the displacement and binding lifetime of a single 
myosin molecule interacting with a single filament can be directly observed.  
Finally, the third step likely to be altered by acidosis is ATP hydrolysis. The 
single molecule experiments performed by Debold et al. (25) suggested that ATP 
hydrolysis was slowed by acidosis. This was suggested based on the average 
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displacement observed for each powerstroke under various conditions: at low ATP (1 
µM), the average displacement was only 2 nm, but this was increased to 6 nm at 10 µM 
ATP and returned to a normal 10 nm at 1 mM ATP. The authors argue that acidosis does 
not alter the size of the powerstroke, because the powerstroke size returned to 10 nm at 
high ATP. Rather, they suggest that ATP hydrolysis is slowed. The logic is as follows: up 
ATP binding, myosin and actin dissociate (step 4, figure 1). However, if ATP hydrolysis 
is slowed, myosin may release ATP and bind to actin, forming a strong bond but 
producing no powerstroke. Thus, in the laser trap assay, an actomyosin binding event 
would be detected but no displacement generated. If such events happened frequently, the 
average displacement of all events would be skewed toward values much less than 10 
nm, as observed. As ATP concentrations increase to 10 µM and 1 mM, myosin could 
release ATP, but a new ATP could quickly take its place, and the crossbridge cycle 
would move forward.  
 Recent work from our group (26, 76) has teased apart which crossbridge steps 
acidosis alters. In the presence of acidosis, we observed a slowing of thin filament 
velocity, which was augmented in the presence of Pi. We postulated that acidosis slows a 
step during ton (possibly the AM.ADP state), and Pi rebinds to this step, causing 
dissociation of actomyosin. This agrees well with a detachment-limited model of 
velocity, where a faster dissociation (caused by Pi) would attenuate acidosis’ effect on 
velocity. We further probed this by measuring velocity in the presence of ADP and Pi. 
Interestingly, Pi could not attenuate the negative effects of ADP on velocity. We 
concluded that there are two myosin-ADP states: AM’ADP and AM.ADP, the transition 
of which is slowed by acidosis. Further, we concluded that Pi can rebind to the AM’ADP 
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state, causing 
dissociation and thus 
limiting acidosis’ 
effects on velocity. 
However, the addition 
of ADP leads to an 
increase in the 
AM.ADP state, a state 
that Pi cannot rebind to and thus cannot affect (see Figure 3.1). Further experiments with 
2-deoxy-ATP (dATP), an ATP analog, showed that dATP can mitigate the effects of 
acidosis in the presence or absence of Pi. We concluded that acidosis must slow the 
weak-to-strong transition, while dATP attenuates this effect. Indeed, previous work has 
suggested that dATP increases the weak-to-strong transition rate (101, 102).  
Though we have made strides toward understanding the effects of acidosis, a 
clearer picture can be obtained by dissecting each step of the crossbridge cycle. Indeed, 
single molecule experiments are necessary to directly observe and measure the steps of 
the crossbridge cycle. One example of the power of single molecule experiments is the 
results obtained from Debold et al. (25) which directly measured that the rate of ADP 
release is reduced in the presence of acidosis, in disagreement with inferences made from 
single fiber data. Additional experiments that could be done to make the conditions more 
physiological would be to measure the rate of certain kinetic steps in the presence of 
regulatory proteins. Finally, if ATP hydrolysis is slowed in the presence of acidosis is 
hard to determine. Debold et al. suggests this is possible, and solution kinetics suggest 
Figure 2.1. Action of Pi rebinding to actomyosin. Pi can rebind to the AM'ADP 
state, but not the AM.ADP state. Acidosis slows the AM’ADP to AM.ADP 
transition. Pi can rebind to this state, causing dissociation of actomyosin and 
thus attenuate acidosis’ effect on velocity. The addition of ADP increases the 
AM.ADP state, a state to which Pi cannot rebind and cannot attenuate velocity. 
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that myosin can release ATP and rebind to actin (107). If any step in the crossbridge is 
slowed by acidosis, myosin’s overall rate of ATP hydrolysis, measured as the ATP 
consumed per second, should decline as the pH is reduced. Interestingly, ATPase 
experiments have been inconclusive, as some actually suggest an increase in ATPase rate 
as pH decreases (100), some show no change (7, 8) while others suggest a 10% decrease 
(109). Clearly, experiments that can tease apart the individual steps of the crossbridge are 
necessary to characterize acidosis’ full effects. 
Acidosis may not only affect myosin’s kinetic steps, but also the force each 
myosin can produce. This possibility has been hypothesized previously based on single 
muscle fiber experiments (82, 100, 105). Some of the evidence is based on assumptions 
of myosin kinetics based on single fiber measurements (100, 105), while Metzger and 
Moss (82) provided convincing evidence of a decrease in force per crossbridge by 
observing a decrease in fiber stiffness relative to the force production of the fiber (82). In 
these experiments, the crossbridges were held in rigor by excluding ATP from the fiber 
bathing solution, and then the fiber was exposed to fast, sinusoidal changes in length so 
that both force and stiffness could be measured. From these experiments, one could 
conclude that force per crossbridge is decreased in the presence of acidosis. One 
confounding factor of these observations is that the changes in stiffness observed with 
acidosis are assumed to have occurred due to alterations in myosin’s mechanical 
characteristics, an assumption that ignores the fact that other proteins within a muscle 
fiber play crucial roles in fiber structure and stiffness. For example, titin is a large protein 
in muscle fibers that passively produces stiffness when a fiber is stretched and this 
stiffness is subject to the concentration of particular molecules, such as Ca++ (73). Titin 
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and other molecules are also sensitive to acidosis and could also therefore lead to the 
observed change in stiffness. To tease apart the direct effect on myosin, experiments that 
measure the strength of the crossbridge in the presence and absence of acidosis are 
necessary. Using a laser trap assay, others have performed such experiments, but only in 
the absence of acidosis (89, 90). Here, once a single actomyosin crossbridge was formed 
in the absence of ATP, the actin filament was pulled to apply a resistive load to the 
myosin molecule. Because the laser trap acts as a spring, the farther the assembly is 
pulled the more force is applied to the myosin, and the force at which the actomyosin 
bond ruptures is recorded. These experiments are therefore feasible to do and could 
provide evidence of the effect of acidosis on the force per crossbridge. If acidosis reduces 
the force per crossbridge, the actomyosin bond should rupture at lower forces than in the 
absence of acidosis. Again, this would provide a direct observation and quantification of 
one of the putative effects of acidosis on myosin function.  
 To summarize our current understanding of the crossbridge cycle, myosin is the 
molecular motor in muscle that cyclically binds to actin to produce force and motion. The 
faster myosin moves through the crossbridge cycle, the faster muscle will contract, and 
the more myosin bind to the thin filament, the more force is generated. Despite what we 
know about myosin’s crossbridge cycle, we do not have a complete picture of how the 
regulatory proteins and Ca++ affect myosin kinetics. We also don’t know how multiple 
myosins work together to activate the thin filament. What follows is an explanation of the 
thin filament regulatory proteins, how they regulate actomyosin binding, and how the thin 
filament is activated. We then describe how specific perturbations affect this activation. 
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Finally, we discuss what gaps exist in our knowledge, and possible experiments that 
could help us fill those gaps.  
Thin Filament Regulatory Proteins 
 
  Thin filament activation is required for a muscle to produce force and motion. 
During muscle activation, Ca++ is released into the cytosol of the muscle cell and allowed 
to bind to troponin. This leads to a slight structural movement of tropomyosin, a 
filamentous protein wrapped around actin. Together, troponin and tropomyosin are the 
regulatory proteins, so called because they regulate myosin’s ability to bind to actin. 
During muscle activation, the shift in tropomyosin exposes myosin binding sites on actin, 
allowing myosin to strongly bind to the thin filament and subsequently produce force and 
motion.  
Troponin has three subunits: the Ca++ binding subunit (TnC), the inhibitory 
subunit that binds to actin (TnI), and a subunit that is bound to tropomyosin (TnT). TnC 
is shaped like a dumbbell with eight major 
helices, labeled A-H (figure 2.2). The first 
four of the helices, A-D, are near the N-
terminus and make up one of the ends of 
the dumbbell. The N-terminus is 
responsible for binding Ca++ during 
activation which subsequently causes a 
subtle movement of the helices B and C 
where they ‘swing’ away from the helices 
Figure 2.2. Structure of TnC. Helices are labeled A-H, 
from N-terminus to C-terminus. The subtle movement 
of the N-terminus is a crucial part of thin filament 
activation. From Herzberg and James 1985 (54). 
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A and D. This movement of the B and C helices exposes a hydrophobic patch on TnC 
where TnI can bind.  
TnI does not inhibit actomyosin binding directly; rather, TnI anchors tropomyosin 
over myosin-binding sites on actin with its long C-terminus tail binding to actin. The C-
terminus tail has two 
particular segments 
crucial for its function: 
the inhibitory sequence 
that binds to actin 
(residues 96-116) and the 
regulatory sequence (also called ‘switch’ sequence) that binds to TnC upon Ca++ 
activation (116-131) (44). Upon Ca++ binding and the subsequent movement within TnC, 
the regulatory sequence swings up and binds to the hydrophobic patch on TnC (figure 
2.3). With the C-terminus of TnI now detached from actin, tropomyosin is no longer 
anchored to actin and can move on the actin surface, which can expose myosin binding 
sites. In summary, the intricate motions of TnC and TnI control tropomyosin movement 
which subsequently dictates myosin strong binding and thus the activation of the thin 
filament. 
The function of TnC and TnI may be altered during muscle fatigue. During 
muscle fatigue, Ca++ levels may drop. In a rested, unfatigued muscle, Ca++ levels can be 
high enough to saturate troponin. However, as fatigue ensues, the pCa level can decline 
to approximately pCa 6 (71). This concentration is not adequate to saturate troponin and 
may lead to submaximal forces. In addition, acidosis may impede the function of TnC 
Figure 2.3. Structure of TnI. The C-terminus of Troponin I binds to actin in 
the absence of Ca++, but binds to TnC in the presence of Ca++. Figure from 
Vinogradova 2005 (123). 
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and TnI. To tease apart which troponin subunit is most altered, chimeras of troponin were 
created, where troponin subunits from both cardiac and skeletal fibers are isolated and 
then mixed. For example, one chimera created in these experiments is TnC from cardiac 
fibers combined with TnI from skeletal fibers. The results from these experiments 
suggested that both troponin subunits are effected by acidosis, but TnC seemed to be the 
most sensitive (6, 30, 86, 93). Further work showed that the first 41 residues of both 
cardiac and skeletal TnC are responsible for this sensitivity (30). Further evidence of the 
effect of acidosis on TnC was provided by isolating TnC and examining its ability to bind 
Ca++ in the presence or absence of acidosis. The percentage of Ca++ bound to troponin 
was measured at various Ca++ concentrations, and acidosis led to less Ca++ binding across 
these Ca++ concentrations (93). Thus, an acidosis-induced reduction in thin filament 
activation likely occurs due to direct effects of acidosis on TnC. Considering that the first 
41 amino acids play a crucial role in TnC function, in the presence of acidosis, the 
hydrogen ions may compete with Ca++ for the Ca++ binding sites on TnC (7, 8, 35).  
  Despite the evidence to suggest that acidosis predominantly affects TnC, some 
data shows that the effect on TnI is more important (22, 24, 131, 133). Cardiac Tn is 
more sensitive to acidosis than filaments with skeletal Tn, shown by a larger shift in the 
pCa-force relationship (86). More specifically, slow skeletal fibers are less sensitive to 
changes in pH, and this difference was hypothesized to be due to differences in TnI. 
Experiments showed that replacing cardiac TnI with slow skeletal TnI resulted in an 
attenuation of the effect of pH on cardiac fibers (131). By examining the amino acid 
sequence of these TnI isoforms, the authors focused on one particular amino acid that 
was different in the C-terminus. This amino acid is located at the 132nd residue on 
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skeletal TnI and the 164th on cardiac TnC, which means this residue is located in the 
inhibitory region of TnI, a crucial part of the subunit that binds to TnC’s hydrophobic 
pocket when the Ca++ is bound. Therefore, this is an area that plays a large role in the 
protein’s function. To test this, TnI was engineered where this one amino acid was 
switched in both TnI isoforms and found that this caused slow skeletal fibers to be more 
sensitive to acidosis (133) while cardiac fibers were much less sensitive to acidosis (22). 
Interestingly, this one residue cannot account for all of the difference in acidosis 
sensitivity across fiber type. This can be ascertained by carefully examining the TnI 
amino acid sequence for slow skeletal, fast skeletal and cardiac fiber types. Both slow 
and fast skeletal TnI have this ‘acidosis resistant’ residue, yet fast skeletal TnI is 
significantly more sensitive to acidosis than slow skeletal TnI. Thus, this one residue 
does not save fast skeletal TnI, and thus other residues or structures in Tn must account 
for this acidosis sensitivity. Further work is necessary to find which residues are 
responsible for these differences. Regardless of the precise mechanism, these chimera 
and single point mutation experiments have provided the framework as to how the effects 
of acidosis can be attenuated. 
Ca++ Activation of the Thin Filament 
 Ca++ activation dictates force and velocity production. During a maximal 
contraction in a fresh, unfatigued skeletal muscle, Ca++ levels are relatively high: almost 
all of the troponins will have Ca++ bound at any given moment, assuming a binding 
constant for Ca++-Tn of ~ 0.5 µM (93). This allows tropomyosin to move freely on the 
actin surface, and allows myosin to bind to the thin filament. However, there are some 
important cases where Ca++ levels aren’t at maximum levels. One example is during 
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muscle fatigue, where during prolonged intense contractions, Ca++ levels in the cytosol 
drop (3, 130). This leads to a decrease in filament activation and thus a decrease force 
and velocity. Another example of submaximal Ca++ levels during contraction are those 
experienced in cardiac muscle. In each cycle of contraction and relaxation that occurs 
with a heartbeat, maximal Ca++ levels are never reached. This means that during 
successive heartbeats, the Ca++ concentration quickly slides up and down the steep 
portion of the pCa-force relationship. As shown before, a typical pCa-dependent 
relationship is shown in figure 1.3.  
These data are fit to the Hill equation, shown here: 
𝑦 = min + 
max − min
1 + 10log(𝑝𝐶𝑎50−𝑝𝐶𝑎)𝑛
 
Where ‘min’ equals the minimum velocity, ‘max’ is the maximum velocity, ‘n’ is the Hill 
coefficient, and pCa50 is the amount of Ca
++ necessary to reach half-maximal velocity.   
The first major outcome is the pCa50. The Ca
++ concentration required to elicit 
half-maximal velocity or force is termed pCa50 and is a measure of Ca
++ sensitivity. A 
lower pCa50 suggests more Ca
++ is necessary to reach a given velocity or force; 
conversely, a higher pCa50 suggests less Ca
++ is necessary. Ca++ sensitivity is important 
considering how steep the pCa-velocity and pCa-force relationship are: subtle changes in 
the Ca++ concentration can drastically change work output of a muscle. Perturbations 
within the muscle cell, drastically alter this relationship, where much more Ca++ is 
necessary to reach a given force output (88). A possible method to examine the effect of 
such perturbations on Ca++ sensitivity is to use the laser trap assay to directly observe 
myosin interact with a regulated thin filament across a range of Ca++ levels. This can also 
be done with a small ensemble of myosin interacting with one regulated actin filament. 
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This would recapitulate in vivo muscle, as many myosins work together to pull on a 
regulated actin filament.   
The second major outcome from a pCa-force relationship is the cooperativity of 
myosin molecules. The Hill coefficient, n, is an indication of this cooperativity. When n > 
1, binding is said to be cooperative, where one binding event accelerates the rate of 
subsequent binding events (45). In the case of the contractile proteins, this suggests that 
one myosin binding event facilitates subsequent myosin binding. Cooperativity has four 
main mechanisms: 1) coupling between the two Ca++ binding sites on fast skeletal TnC, 
2) coupling between Ca++ binding sites down the thin filament, 3) myosin strong binding 
inducing Ca++ binding to TnC, and 4) myosin strong binding inducing movement of 
tropomyosin into an open state so other myosin can more easily (44).  
There is some evidence for the first mechanism contributing to cooperativity, 
though not by much. There is evidence that the two Ca++ binding sites on fast skeletal 
TnC bind cooperatively, leading to a Hill coefficient of 1.2 (46). This mechanism isn’t 
possible in cardiac TnC, which only has one Ca++ binding site. Interestingly, if skeletal 
TnC is added to cardiac thin filaments, cooperativity is observed (4). Regardless of this 
cooperativity, the first mechanism of cooperativity is not enough to explain the highly 
cooperative action observed in fibers.  
There is also evidence for the second mechanism, where Tn along the thin 
filament are able to cooperatively bind Ca++. By using fluorescent probes on Tn, Ca++ 
was shown to bind cooperatively down the thin filament (46, 50). Other experiments 
suggested this mechanism of cooperativity by performing partial extractions of TnC and 
observing cooperativity decrease (10, 87).  
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Like the first two mechanisms, the third mechanism likely plays a small role, but 
there is evidence that myosin binding can cooperatively increase Ca++ binding to Tn, 
Experiments using fluorescent probes on Tn (50) suggest that Ca++ binding to Tn is 
influenced by myosin. Other experiments have tested this hypothesis using myosin 
modified with BDM, which keeps myosin in a weakly bound state (93). However, some 
have suggested that only rigor myosin have this effect, which leads to the question if this 
mechanism would occur under physiological conditions (11, 39).  
The fourth mechanism is most likely to have the biggest effect in generating 
cooperativity and thus Hill coefficients greater than 1.5. This has been demonstrated 
multiple times by either decreasing ATP or by increasing ADP (40, 48, 56, 104). The 
former would increase rigor myosin, while the latter would increase M.ADP myosin, 
both of which can strongly bind to the regulated thin filament and help neighboring 
myosin to bind. Similarly, NEM modified myosin were used to activate the thin filament 
(111). Additional evidence for the fourth mechanism comes from experiments with 
partial TnC extractions: by removing TnC, the tropomyosin stays in the blocked state and 
prevents myosin from communicating. Finally, creative experiments were done with 
fluorescent S1 myosin, which were observed binding to a native myofibril. S1 bound to 
the overlap region (of the thick and thin filament) four times more than the nonoverlap 
region, suggesting that the myosin in the thick filament helped the fluorescent S1 bind to 
the overlap region. These experiments were done with both rigor and M.ADP S1 under 
high Ca++ and low S1 conditions. To further support myosin-myosin cooperativity, as S1 
was increased in this experiment, the S1 would bind to the nonoverlap region in highly 
cooperative manner (112). Thus, there is a large amount of evidence to suggest that 
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myosin-myosin cooperativity is the biggest contributor to the highly cooperative nature 
of the pCa-force relationship.  
 How cooperativity occurs is a dynamic and complex process and has been 
difficult to characterize. Indeed, recent innovative approaches (29) and sophisticated 
mathematical models (42, 84, 126) have tried to describe this phenomena quantitatively. 
Why is it difficult to quantify and characterize cooperativity? This is because 
cooperativity involves both elements of time and space, where myosin binding to actin is 
short-lived (as short as 2 ms) and thus only activates the filament for a very short period, 
and will only facilitate binding of other myosins that are nearby. Why is myosin 
necessary to activate the thin filament? Previous work (52) suggested that tropomyosin 
worked like a switch that could either be open, allowing myosin binding, or blocked, 
preventing myosin binding. An alternative hypothesis suggests that tropomyosin explores 
three states: blocked, closed, and open. In both models, tropomyosin blocks actomyosin 
binding sites in the absence of Ca++. In the latter model, called the three-state model, Ca++ 
binding does not cause tropomyosin to completely open the actomyosin binding sites; 
rather, it only slightly exposes them, and so this state is called the closed state. Finally, 
when a myosin binds to actin, myosin pushes the tropomyosin to the open state. An 
important note is that tropomyosin is dynamic, and that even in the absence of Ca++ 
tropomyosin has a finite probability of being in the open state. For example, previous 
work has quantified this probability, showing that even in the presence of Ca++, 
tropomyosin is in the closed state 75% of the time while it is in the open state 98% of the 
time when myosin binds to actin (45, 81). This three state model is further supported by 
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biochemical experiments (72, 81, 118), in vitro motility assay (62), fiber studies (111), 
modeling (62, 81), and structural studies (19, 98, 108, 122, 125). Clearly, actomyosin 
binding plays a crucial role in thin filament activation, but how does this effect other 
myosin molecules? When one myosin pushes tropomyosin into the open state, this state is 
propagated down the thin filament, where other actin monomers now have their binding 
sites more exposed. To 
understand cooperativity, the 
distance down the filament that 
tropomyosin movement is 
detected is a crucial measure. 
This, of course, depends on how 
rigid tropomyosin is: if 
tropomyosin is rigid like a metal 
rod, when one myosin binds to 
actin the whole tropomyosin structure should be pushed to the open state. On the other 
hand, if tropomyosin is soft and flexible, the open state may not even propagate down the 
tropomyosin molecule for the next myosin. In reality, the data suggests that tropomyosin 
is semi-rigid: experiments using the laser trap assay have shown that one myosin binding 
can facilitate another that is approximately 110 nm away (62). However, other work has 
shown that tropomyosin may be more flexible than previously thought, as determined by 
its persistence length (77). Persistence length is a common measure of the stiffness of 
filamentous proteins, where pieces of the beam that are closer together than the 
persistence length are correlated and represented as part of a semi-rigid rod, while pieces 
Figure 2.4. Cartoon of the 3-state model of thin filament 
activation. Actin (light gray) and tropomyosin (dark gray) in the 
blocked (B), closed (C), and open (D) state. Areas on actin where 
myosin binds weakly (green) and strongly (red) are highlighted. 
Figure from Gordon et al. 2001 (45). 
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farther apart than this threshold are not correlated. Previous findings suggest that 
tropomyosin’s persistence length anywhere from 40-500 nm (62, 77, 80, 97, 103, 122). 
Such various values make determining how far cooperativity is propagated down the thin 
filament quite difficult. Furthermore, neither the term ‘persistence length’ or ‘cooperative 
length’ capture the physiological complexity of cooperativity. Are all myosins within this 
distance treated equally? For example, if the cooperative length was 100 nm, do both the 
myosin 10 nm away and the myosin 90 nm away increase their chances of strong binding 
to the thin filament? Or is the probability of a second myosin binding increased if it is 
closer to the first myosin that is bound? Sophisticated mathematical models of thin 
filament activation suggest the latter (126, 127), but experimental data with small 
ensembles of myosin are necessary to confirm this, especially in the presence of 
submaximal Ca++ levels. Such experiments would provide crucial information on how 
both Ca++ and myosin strong binding play a role in thin filament activation. Additional 
experiments in the presence of acidosis can explore this effect on cooperativity. 
 To successfully model thin filament activation and subsequent muscle output, a 
universal model must 1) take into consideration many sets of data and be able to match 
the data, 2) explain and match data across all scales of muscle, from the whole organ to 
the single myosin, 3) be within the limits of current computational power, and, of course, 
4) explain data across different activation conditions, such as various Ca++ levels, various 
myosin concentrations, and various metabolite concentrations, such as ATP, Pi, etc. 
 Some models use Monte Carlo simulations to predict behavior on a sarcomere 
level (14). This model is able to describe activation, even at low Ca++ levels (1). 
Unfortunately, Monte Carlo simulations are computationally heavy, and can only model 
33 
 
small parts of muscle (in this case, one thin filament). Further, this model has not been 
tested in its ability to explain whole muscle findings or data with metabolic perturbations.  
 Other models are designed to explain whole muscle findings using molecular 
inputs. For example, Tanner et al. developed a model that recapitulates the lattice 
structure of muscle (116). They argue that this 3D model is better than a comparative 2D 
model. Though informative, this model has also not been tested with metabolic 
perturbations. In addition, a minor critique is that rate constants used in the paper come 
from three different research groups. These rate constants were determined from 
myofibril or muscle fiber data. Though reliable, these data are not determined through 
direct observation. On the other hand, data collected from assay such as the laser trap 
assay are from direct observation and can provide the most reliable picture of the actions 
of thin filament activation on the molecular level.  
 Though many models exist, the model that seems to fit all of our criteria is created 
by Walcott (126). This model has been tested with many sets of data across the scale of 
muscle, especially with single molecule and small ensemble data sets (28, 62, 127). A 
large benefit of this model is that this model uses findings from a specific cohort of 
researchers (28, 62, 128) which ensures fidelity. This model uses the more computer 
friendly partial differential equations (PDEs) to perform calculations, as opposed to 
Monte Carlo simulations, which, while useful, can be computationally heavy because 
they aim to characterize each molecule’s behavior at any given moment. Finally, and 
possibly most important, this model can make predictions across all muscle scales, from 
the single myosin molecule up to whole muscle.  
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The R146G Mutation 
A major goal of this work is to better characterize thin filament activation so that 
we can apply that knowledge to muscle fatigue or diseases caused by point mutations. A 
key way the knowledge can be applied is to compare the molecular details of activation 
under normal conditions to situations that arise with mutated proteins. This is particularly 
relevant to cardiac muscle, where a single point mutation can disrupt normal activation, 
leading to abnormal force production and many times leading to lethal cardiomyopathies 
(79). The most common mutations that lead to such drastic outcomes occur in the 
sarcomere, including myosin, myosin binding protein C, tropomyosin, or troponin (79). 
While the many common mutation sites within these three proteins are actively being 
studied, one in particular, the R146G mutation in TnI, has been a quagmire and may 
affect both myosin kinetics and Ca++ binding dynamics (12, 34, 60, 69, 70, 75, 114, 129, 
132, 138). Considering this, we felt this particular mutation was worth examining further. 
Cardiac Troponin Structure 
Cardiac troponin is slightly different than the skeletal isoform discussed earlier. 
The two major differences are that cardiac troponin C has only one Ca++ binding site on 
the N-terminal, and that cardiac troponin I has 30 more amino acids in the N-terminal. 
These 30 more amino acids cause a shift in the homologous structures. For example, the 
inhibitory region of skeletal troponin I is located near amino acids 96-116, while the 
inhibitory region of cardiac troponin I is located near amino acids 126-146. These places 
our mutation of interest within the inhibitory region of cardiac troponin I. This particular 
mutation involves a switch from a relatively large, charged arginine to the small, 
hydrophobic glycine. Exactly how this alters the structure of TnI is difficult to say. As 
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some have pointed out, many cardiomyopathic mutations are clustered in flexible regions 
of proteins, which makes obtaining structural data with cryo-EM or crystallography quite 
difficutl (12). This flexibility may lead to the mutation’s negative effects on myosin and 
thin filament activation.  
Effect of R146 on Myosin 
Interestingly, the R146 mutation seems to affect myosin’s function, even at 
maximal Ca++ activation. At maximal Ca++, myosin binding is expected to be the limiting 
factor in force production (41). Yet, with this mutation, there is evidence that force is 
reduced at maximal Ca++ (70, 129). Interestingly, these results are equivocal, where 
others have shown no significant decline in force (114, 132). The discrepancy may be due 
to differences in expression of the R146G mutation across transgenic experiments. James 
et al showed that differences in expression level can alter the phenotype (60). 
Specifically, mice that expressed a larger percentage of R146G relative to wild-type 
troponin had a lower survival rate. The cause of the observed reduced force in (70, 129) 
is difficult to explain, considering high Ca++ levels should fully activate troponin and 
tropomyosin, and any limit in force would be due to a limit in myosin kinetics or 
mechanics. Indeed, some have proposed that the R146G alters myosin’s crossbridge force 
(129). This is surprising, as TnI interacting with or altering myosin’s function is 
unexpected. Others have found that the cause and effect relationship is different: using 
FRET, Zhou (138) measured the Ca++ dependence of the TnC-TnI interaction in both 
wild-type and R146G filaments, and found that the presence of S1 myosin induced a 
large shift in the pCa50 in mutant filaments but not in wild-type. These data suggest that 
S1 somehow influences TnC-TnI dynamics in the presence of the R146G mutation.  
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In addition to a decline in force, the mutation causes a decline in ATPase activity 
at maximal Ca++ (70, 114), though others have found no decline in this measure (34, 
129). The discrepancy in results does not seem to be due to differences in methods, 
considering Lang et al. 2002 and Elliot et al. 2000 both used reconstituted thin filaments 
in solution.  
Finally, the R146 mutation has been shown to reduce peak velocity at maximal 
Ca++ in a motility assay (12) but not in fiber assay from transgenic mice (60). Here, the 
difference could be attributed to the overall percentage of R146G troponin. In a motility 
assay, the percentage of any given protein can be easily controlled (in this case, 100% of 
the troponin in the regulated thin filaments was mutated) while transgenic models rarely 
achieve 100% inoculation. Though the percentages achieved in James 2000 (40-80%) are 
a better representation of the expression levels in patients with this cardiomyopathy, the 
decline in motility shown in Brunet et al. provides insight into how this mutation affects 
force and motion. Brunet et al. propose a model where the R146G mutation contributes to 
a very flexible TnI subunit. The result is incomplete inhibition of actomyosin binding in 
the absence of Ca++ and incomplete activation upon Ca++ binding, suggesting the 
mutation does not affect myosin directly.  
Effect of R146 on Thin Filament Activation 
The more obvious effect of a mutation in troponin is the effect on Ca++ sensitivity. 
Indeed, the R146G mutation leads to an increase in the Ca++ sensitivity, indicated by an 
increase in the pCa50, in ATPase measures either in solution (34, 114) or in isometric 
fibers (129). Similar shifts in the pCa50 have been found in isometric force measures of 
fibers from transgenic mice, transfected mice, and in fibers following a Tn exchange that 
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contained the R146G mutation (60, 70, 114, 129, 132). However, there is data showing 
that the R146G mutation has no effect on force in transgenic mice or following Tn 
exchange (69). Finally, the shift in Ca++ sensitivity has recently been seen in the pCa-
velocity relationship as well (12). In addition to finding an increase in Ca++ sensitivity, 
many have found that the R146G mutation is not sufficient to completely inhibit ATPase 
at low Ca++ (34, 70) nor is it sufficient to completely prevent force production (69, 70, 
114, 129).  
What can explain the overall findings for the R146G mutation? How does this 
mutation leads to enhanced ATPase and force at low Ca++ but reduced ATPase and force 
at high Ca++? One model suggests that the R146G mutation leads to weaker bonds to both 
actin (34) and to TnC (75). A weaker bond to actin under low Ca++ conditions would 
increase the probability of TnI detaching from actin, allowing tropomyosin to move on 
the actin surface and eventually will lead to a higher probability of myosin binding to 
actin. A weaker bond to TnC, on the other hand, would lead to a lower probability of TnI 
binding to TnC upon Ca++ activation. This may suggest that TnI is moving freely or TnI 
may still be bound to actin, despite the presence of Ca++. Another possibility is that the 
mutated TnI interacts with myosin under high Ca++ conditions. As stated earlier, this 
interaction seems unlikely but there is evidence to suggest that the mutated TnI affects 
myosin’s crossbridge force. If this TnI-myosin interaction is possible, the mutated TnI 
may not only myosin’s mechanics, but also its kinetics. More specifically, experiments 
examining the effect of the mutation on myosin’s on-rate as well as myosin’s duty cycle 
would add to our understanding of this mutation. While determining the precise structure 
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and dynamics of R146G TnI is very difficult, determining how the mutation affects 
myosin kinetics can be easily examined in an in vitro motility assay.  
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CHAPTER 3 
METHODS 
To achieve the aims of this project, the laser trap assay and the in vitro motility 
assay were used. As alluded to before, in vivo studies as well as single muscle fiber and 
motility experiments have led to our current understanding of working muscle. Though 
informative, more precise techniques are needed to understand the molecular basis of thin 
filament activation and muscle contraction. To achieve this, the laser trap can be used to 
examine the molecular details of the contractile proteins. Single muscle fibers contain 
billions of myosin molecules as well as a complex array of other proteins, but the laser 
trap assay allows for the direct observation of a single myosin molecule interacting with a 
single actin filament. Here, we can directly observe specific steps of the crossbridge 
cycle, a feat not achievable with muscle fibers. The laser trap assay can be used to better 
understand actomyosin binding kinetics, force production of single myosin molecules, 
and activation of the regulated thin filament (5, 15, 25, 29, 37, 62, 121). The laser trap 
assay was used to directly observe, on the nanometer and millisecond scale, the binding 
and force-producing capacity of an individual and small ensembles of myosin. 
Using this assay, we first examined the effects of Ca++ on a single myosin’s 
ability to bind to a regulated thin filament. We measured the binding events per second as 
well as each event’s duration. Second, we examined how a small ensemble of myosin 
interact with a regulated thin filament. We directly observed the how a small ensemble of 
myosin work together in a cooperative fashion to pull on the actin filament to generate 
force and motion in a Ca++ dependent manner. These experiments enabled us to 
recapitulate the pCa-force relationship on the molecular level. In addition, this particular 
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experiment was one of the best representations of in vivo muscle because of our use of a 
small ensemble at relatively high (100 µM) ATP concentrations.  
The in vitro motility assay is designed to observe unloaded velocity of actin 
filaments as they are propelled by myosin in a variety of conditions. In our experiments, 
we manipulated ATP and Ca++ and measure the resulting velocity. This technique, called 
a “rigor activation” assay, will provided insight into thin filament activation. This is 
because Ca++ affects regulatory protein dynamics, while ATP affects myosin’s kinetics, 
in particular, how long myosin stays bound to actin in the rigor state. Because both Ca++ 
and myosin strong binding play a role in thin filament activation, this assay provides 
insight into the dynamics of each.  
We also used the in vitro motility assay to examine the effects of a particular 
troponin mutation, R146G, on thin filament activation and myosin kinetics. To examine 
these effects, we first measured unloaded velocity in a Ca++ dependent manner and 
generated a pCa-velocity relationship. We then performed a duty cycle experiment, 
where the number of myosin heads available to the regulated thin filament was 
manipulated and the velocity of each filament was measured. These data were then fit to 
a duty cycle equation (120):  
𝑉 = 𝑉𝑚𝑎𝑥 ∗ (1 − (1 − 𝑓)
𝑁) 
to determine the percentage of time myosin is strongly bound to the filament. In 
this equation, V is the measure velocity of a filament, Vmax is the maximum velocity, f is 
the duty ratio, or the percentage of time myosin is strongly bound to actin, and N is the 
number of myosin heads interacting with the filament. As V changes as a function of N, 
and the data can be fit, where Vmax and f are determined by the fit. Finally, we then 
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manipulated ATP in a motility assay to examine if the R146G mutation alters myosin’s 
ADP-release rate, which directly affects myosin’s on-time. 
Overall, the proposed experiments have allowed a better understanding of the 
molecular details of thin filament activation. The experiments also provide insight into 
how thin filament activation is altered by troponin mutations. This will set a foundation 
for future work that can examine this mutation and others that lead to cardiomyopathies 
and the development of therapeutics to combat the negative effects associated with the 
mutations.  
Laser Trap Assay 
Background 
 
The laser trap assay was used to directly observe either single myosin or a small 
ensemble of myosin generate force and motion by interacting with a thin filament. To do 
this, a powerful, densely focused beam of light traps two 1 μm glass beads which are then 
attached to each end of a thin filament. This bead-filament-bead set up, or “dumbbell” set 
Figure 3.1. Cartoon of the 3-bead assay. Myosin is randomly oriented on the microscope slide surface, 
occasionally located on a pedestal bead. A bead-filament-bead assembly, trapped by laser light, is put in close 
vicinity to the pedestal so single molecule interactions can be observed and measured. Figure courtesy of Mike 
Woodward. 
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up, is positioned near a 3 μm bead on the microscope slide surface that is sparsely coated 
with myosin (figure 3.1). This set up enables one myosin molecule or an ensemble of 
myosin molecules to interact with the actin filament. As myosin pulls on the thin 
filament, the position of one bead is detected by a quadrant photodiode, which can 
discern nanometer and millisecond motions, and the force exerted on the filament by the 
myosin can be calculated.  
Hardware and Software 
The optical light path used to form the laser trap is very similar to that previously 
described (28) with minor changes. Briefly, a 5 W, infrared (1090 nm) laser beam (SPI 
Lasers, Santa Clara, CA) is timeshared between two locations at 10 kHz using two 
orthogonally (x and y) oriented acousto-optic deflectors (AODs) (DTD-274HA6, Intra 
Action, Bellwood, IL). An AOD serves to deflect a beam of light as a function of the 
radiofrequency transmitted through the medium. By altering the frequency, the beam of 
light and thus the trapped bead can be steered. The AOD is driven by a custom-built 
digital controller (Elliot Scientific, Hertfordshire, United Kingdom) that interfaces with a 
personal computer via a field-programmable gate array card (PCI-7830R, National 
Instruments, Austin, TX) and custom software developed using the real-time module of 
LabView version 8.6 (National Instruments).  
Displacements of one of the trapped beads were determined by imaging the 
interference pattern of the bead onto a quadrant photodiode (QD) (G6849, Hamamatsu 
Photonics, Hamamatsu City, Japan) conjugate with the back focal plane of the condenser 
(32). This displacement signal was digitized via a National Instruments data acquisition 
module (USB 9162) and collected at 5 kHz. Coarse movements of the microscope stage 
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were made using a manual micrometer-driven stage with a capacitive servo-feedback 
piezoelectric substage (Nano-Bio200, Mad City Labs, Madison, WI) that can generate 
nanometer movements for fine control. The fluorescent thin filament was then visualized 
using an intensified CCD camera (Stanford Photonics, Palo Alto, CA) while 
simultaneously visualizing the silica beads in bright field using a CCD camera, which 
interfaced with the PC. 
Trap Stiffness Calibration 
The force of the laser light applied to a 1 µm bead behaves as a simple linear 
spring, where F = k * x, where F is the force, k is the spring constant of the trap (or 
stiffness) and x is the distance the bead is from the center of the trap. The stiffness of our 
optical trap was determined two different ways: the equipartition method and the power 
spectral density method. The equipartition method relies on the relationship between 
thermal energy and the spring energy. The thermal energy for one-dimensional diffusion 
is ½kBT, where kB is the Boltzmann constant and T is the temperature of the 
environment. The spring energy of a bead in an optical trap is ½kx2, where x2 is the 
variance in the bead’s position. Therefore, we can derive: 
𝑘𝑡𝑟𝑎𝑝 =
𝑘𝐵 ∗  𝑇
𝑥2
 
We measured the variance of the bead’s position and determine the stiffness of the trap. 
To confirm our calculations, we used the power spectrum density. For a sphere in 
solution, the drag coefficient, γ, is calculated as: 
𝛾 = 6 ∗ 𝜋 ∗  𝑛 ∗ 𝑟 
Where n is the viscosity of the solution and r is the radius of the bead. The power spectral 
density gives the function: 
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𝐹(𝑡) =
𝑘𝐵 ∗ 𝑇
2 ∗ 𝜋2 ∗ 𝛾 ∗ (𝑓2 + 𝑓𝑐2)
  
Where fc is the corner frequency, which is equal to: 
𝑓𝑐 =  
𝑘𝑡𝑟𝑎𝑝
2 ∗  𝜋 ∗ 𝛾
 
And thus, the stiffness of the trap, ktrap, can be calculated.  
Proteins 
Whole myosin and actin were purified from chicken pectoralis muscle based on 
previous methods (78, 92). SDS gels and High Performance Liquid Chromatography 
(HPLC), tools used to separate proteins by size and charge, demonstrated the high purity 
of the proteins. Myosin was stored in glycerol (50% v/v) at -20°C for up to 1 year. The 
purified actin filaments were fluorescently labeled and stabilized with TRITC/phalloidin 
and coated with biotin and stored at 4°C. Wild-type skeletal troponin was purchased (Life 
Diagnostics, West Chester PA), while troponin variants will be generously provided by 
our collaborator Dr. Tomo Kobayahsi at the University of Illinois. Dr. Tomo Kobayashi 
prepared and provided troponin as described here. Recombinant mouse cardiac TnI, TnC, 
and TnT was inserted into pET3d vector and expressed using BL21(DE3) cells. 
Expression of the correct sequence was confirmed by DNA sequencing. The subunits 
were purified, reconstituted, and frozen in liquid nitrogen. The troponin variants were 
divided into single experiment sized aliquots, snap frozen in liquid nitrogen, and stored at 
-80°C until the day of the experiment.  
Solutions 
On the day of an experiment, the purified chicken pectoralis myosin was diluted 
to 200 μg/mL in myosin buffer (300 mM KCl, 25 mM Imidazole, 1 mM EGTA, 4 mM 
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MgCl2, 1 mM DTT). An equimolar concentration of purified chicken pectoralis actin was 
added to this solution, in addition to 1 mM ATP. This solution was centrifuged at 
400,000 g for 20 minutes to separate live myosin from ‘dead-head’ myosin that cannot 
hydrolyze ATP. The ‘dead-head’ myosin bind to the actin and pellet, while the live 
myosin stays in solution. This solution was extracted and diluted so the myosin was at a 
final concentration of 0.1 µg/mL for single molecule experiments or 10 µg/mL for 
experiments with small myosin ensembles.  
To create reconstituted regulated thin filaments, on the day of an experiment 1 
µM actin was mixed with 0.25 µM troponin and 0.25 µM tropomyosin and allowed to 
incubate for 3 hours. This solution was then diluted to bring the actin concentration to 10 
nM. Full reconstitution and thus full regulation was confirmed by performing an in vitro 
motility assay with 100 µg/mL myosin and the regulated filaments at pCa 10. After the 3-
hour incubation, the actin was diluted in a low salt actin buffer (25 mM KCl, 25 mM 
Imidazole, 1 mM EGTA, 4 mM MgCl2, 1 mM DTT) to 10 nM. BSA was diluted in actin 
buffer to 0.5 mg/mL. The 1 µm trapping beads were incubated with 0.5 mg/mL 
neutravidin and allowed to incubate for 3 hours. After 3 hours, the beads were diluted in 
actin buffer and sonicated to remove excess neutravidin that did not bind tightly to the 1 
µm beads. This washing process was repeated and the beads were then diluted in 500 µL 
of actin buffer.  
The final buffer for the laser trap assay was composed of actin buffer with 
experiment-specific additions. For pCa-force experiments, a calculated amount of Ca++ 
was added to reach a specific Ca++ concentration and 100 µM of ATP was used. For 
single molecule binding experiments that examine on and off rates, 10 µM of ATP will 
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be used. For all experiments, the ionic strength was held constant at 95 mM by adjusting 
the amount of KCl added to the final buffer. The pH of the final buffer was set to 7.4. 
Buffer recipes will be determined using a computer algorithm with known chemical 
binding constants, with adjustments for temperature, pH and ionic strength (WinMaxC) 
(52). All final buffers contained an oxygen scavenger system (1725 mg glucose, 75 mg 
glucose oxidase, and 14 mg catalase) to prevent photobleaching of the actin filaments.  
Laser Trap Assay Protocol 
 Myosin was added to the flow cell and allowed to bind to the nitrocellulose-
coated surface for 2 minutes. BSA was flowed in and allowed to incubate for 5 minutes 
to ensure actin does not attach to the nitrocellulose surface. While this incubation occurs, 
the neutravidin beads were sonicated to break apart any coagulation. 3 µL of the beads 
were added to 181 μL of final buffer. This aliquot was vortexed to ensure a homogenous 
mixture of beads. 8 μL of the 10 nM labeled actin and 4 µL of each regulatory protein at 
5 µM was added to this final buffer. The flow cell was placed on the microscope. Finally, 
the final buffer was added to the flow cell. 
 In the flow cell, we trapped 2 of the 1 µm beads. A labeled, regulated, biotin 
coated actin filament was secured between these two glass beads. Once a bead-actin-bead 
complex was assembled in the laser trap, the filament was pulled taught, with a 
pretension of 4 pN. The complex was lowered to a 3 µm bead coated with myosin. As the 
QD determines the position of one of the neutravidin beads, actomyosin activity can be 
observed. Actomyosin activity is confirmed by a directional displacement of the bead 
from the laser trap, as determined by the QD. Once activity is observed, a 5 second 
recording was taken. 
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Data Analysis 
The positional data of the 1 µm bead was measured in mV, which was converted 
to nanometers after an internal calibration. For the data collected with a small myosin 
ensemble, the data was then converted to forces, measured in pN, by multiplying the 
nanometer displacements by the stiffness of the laser trap. In this way, we determined the 
force produced by a small myosin ensemble.  
To objectively detect single molecule events, an analysis called the Page method 
was used (66). Essentially, this method looks for a decrease in variance in the signal, 
which occurs when myosin strongly 
binds to actin. If this decrease in 
variance lasts long enough, the 
program detects it as an event. More 
specifically, the original signal is 
corrected to zero. The program then 
examines each point and calculates 
the probability of the data point 
being part of an event based on how 
far the point is from zero. If the 
probability is relatively high, a value is 
added to a cumulative sum, whereas each 
succeeding point that has a high probability 
will also add to the sum. Once this sum reaches a pre-determined threshold, the program 
Figure 3.2. Example of the Page method. Single 
molecule recordings were examined using the Page 
Method. A sliding window is used to determine the 
variance of the window. A low variance will lead to a 
cumulative sum. An event is counted once the 
cumulative sum reaches a predetermined threshold. 
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recognizes the data points to be part of an event. A sample trace and the corresponding 
cumulative sum is shown in figure 3.2.  
For force measurements with small myosin ensembles, each recording was 
analyzed with a custom Matlab computer program. A brief description of the program is 
as follows: first, the program examines all the data and determines the baseline of the 
trace, where myosin and the thin filament are not bound. The program then examines 
each data point in the file, checking if it is at least 8 nm above the baseline. The 8 nm 
threshold is based on previous literature suggesting that when myosin binds to actin, it 
generates a powerstroke that is at least 8 nm (15, 119). Therefore, this is the first criteria 
to see if myosin has bound to actin. This minimum 8 nm displacement must occur for 10 
consecutive milliseconds for the program to determine that a binding event has occurred. 
The 10-millisecond criterion is based on the expected duration of a single myosin-actin 
interaction. This interaction is dependent on the length of the actin-myosin-ADP state and 
the myosin-actin rigor state. Assuming an ADP release rate of 100 to 350 per second (5, 
128) and an ATP binding rate of 2 to 7 x106 * s-1 * M-1 (5, 91), approximately half of the 
single myosin-actin binding events should last 10 ms or longer at our experimental 
conditions of 100 µM ATP. Once the program determines that an event has occurred, the 
time at which the event began is determined. In addition, if this is not the first event in the 
recording, the program calculates how much time has passed since the previous event 
ended. This is a useful measure that provides insight into the binding frequency, a 
measure that is expected to change under the various conditions tested, particularly the 
different Ca++ concentrations. Finally, when the event has ended, determined when the 
recording has dropped back down to baseline, the duration of the event is calculated. In 
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addition, the program examines the event and finds the 10 ms region that contains the 
highest average mV signal. This average is then converted to pN and this peak force is 
recorded. Thus, overall, the program can determine when an event occurs during a 
recording, and then determines the duration and peak force of each event.  
 Some of our experimental conditions, including single myosin molecule 
experiments or conditions with low Ca++ (pCa 9), required a different analysis strategy. 
Under these conditions observing distinct single myosin-actin binding events in the 
recording is difficult. However, actomyosin 
binding significantly reduces the noise in the 
force recording (figure 3.3). This occurs due 
to the stiffness of the myosin-actin bound, 
which reduces the movement of the actin 
filament and thus the detected 1 µm bead. 
Again, an in-house Matlab program will 
examine the force recordings to determine 
when an event has occurred. This program is very similar to the one used for myosin 
ensembles, except instead of using an 8 nm displacement as a criterion, we will use a 
70% drop in the variance of the signal. This cut-off was determined based on our current 
estimates of the myosin-actin stiffness of 0.3 pN/nm and the expected decrease in the 
variance based on this stiffness. Further, preliminary experiments have shown that this 
threshold works well, as data recordings showed events, while control recordings (ones 
where a recording was collected with the dumbbell set up positioned away from a 3 µm 
pedestal bead and therefore where no myosin-actin binding could occur) showed no 
Figure 3.3. Example of capturing events with 
Brownian motion. During a recording, the signal of 
the 1um bead is noisy (n) but during a myosin-
actin binding event (e) the variance drops 
significantly. Figure from Veigel and Molloy (121). 
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events. Though force measurements were not taken with this program, the duration and 
time between can be measured as before. Therefore, we can gain insight into the on and 
off rate of a single myosin molecule under many different conditions.  
A critical measure for laser 
trap experiments is the height of 
the dumbbell set up relative to the 
pedestal bead. Knowing that the 
thin filament is close enough to the 
pedestal bead to allow myosin 
binding is important as this can 
affect the frequency of myosin 
binding; this value must be 
consistent from one condition to 
another. Therefore, during a 
recording we recorded a bright field image of the 3 µm bead. The height of the dumbbell 
set up was determined by analyzing the airy disc diffraction pattern of the 3 µm bead. 
This analysis can be used to determine axial position of micrometer particles (136). We 
have applied this technique to our microscope and took approximately 30 images at 
known heights, from 2.5 µm to 4.5 µm, and established a linear relationship between the 
airy disc radius and its height (figure 3.4). These heights were recorded by driving the 3D 
piezoelectric stage with nanometer resolution. A custom Matlab program was then 
written to calculate future images based on our standard curve. Testing the model with 
additional images at known heights showed that the model was accurate within 100 nm. 
Figure 3.4. Determination of trap height. Top: Images taken of 
the 3 µm pedestal bead at different heights in the laser trap 
assay using a brightfield camera. Bottom: Calculating the airy 
disc created by the pedestal bead shows that the radius is 
linearly related to the z-position in the laser trap.  
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Our data collected at high Ca++ shows that heights up to 3.5 µm above the surface allow 
actomyosin binding, but heights above this do not. As stated earlier, some conditions 
resulted in very discrete and scarce events. Therefore, some data recordings may show no 
events at all, but if the corresponding height is within 3.0 to 3.5 µm, the data recording 
was considered in the final analysis. Conversely, if the file is collected above 3.5 µm, the 
data recordings were discarded.  
Statistical Analyses 
 Histograms were generated for all experiments performed with a small ensemble 
of myosin, showing the relative frequency of forces, durations, or time between events. 
These measures were not normally distributed (28) and therefore a nonparametric 
Kruskal-Wallis analysis of variance was performed to identify significant differences 
across conditions, with differences identified using the method of Dunn (31).  
For our experiments examining on and off rates of single myosin binding events we used 
a one-way ANOVA comparing the different pCa concentrations. All statistical 
procedures will be performed in SigmaPlot v11.0 (Systat Software, San Jose, CA) with 
the alpha level set at p < 0.05. 
Mathematical Model 
 A major goal of this dissertation was 
to deconvolve the role of Ca++ and myosin 
strong binding during thin filament 
activation. To do this, we compared our 
single molecule binding results with our 
small ensemble results using a mathematical 
Figure 3.5. Cartoon of the 4-state kinetic model. 
Myosin transitions from a weakly bound state (1) to a 
strongly bound state (2). It then releases ADP, 
entering a rigor state (3). ATP binds to myosin, 
causing actomyosin dissociation (4). 
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model. This mathematical model incorporates a four-state kinetic model of the 
crossbridge cycle (figure 3.5), with global and local coupling. Here, global coupling 
refers to myosin molecules that affect each other’s kinetics through the thin filament. For 
example, as a leading myosin pulls on the actin filament, a trailing myosin will feel this 
pull, release ADP and subsequently release actin. This load-sensitivity of myosin is well 
documented (47, 110, 121). Local coupling refers to myosin’s ability to influence 
neighboring myosin and their ability to bind to the thin filament. The model employs a 
flexible chain model, where tropomyosin is treated as a flexible chain that can be 
distorted by myosin strong binding. The model depends on two key parameters: ε(Ca++), 
the single myosin molecule transition from weak to strong binding as a function of Ca++ 
relative to the weak to strong transition rate in the absence of the regulatory proteins, and 
ℓ, the coupling distance, such that two myosin within this distance that are strongly 
bound to the thin filament completely activate the area of the filament between them, but 
act independently if they are separated by a distance greater than ℓ. The model has fit 
data from multiple scales, including single molecule, small ensemble, and motility data 
(28, 126-128). In previous work, this model has assigned ℓ to equal 400 nm. Note that 
this is not the same as the cooperative unit length, as ℓ only implies partial activation. For 
example, in this model, unattached myosin that are close to a strongly bound myosin are 
much more likely to bind than myosin that are farther away (but still within 400 nm). We 
assumed that this ℓ is independent of Ca++.  
 The parameter ε is defined with the following equation: 
ε = ε𝑚𝑖𝑛
1−𝜃 ∗ ε𝑚𝑎𝑥
 𝜃  
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where θ is the fraction of Tn bound to Ca++. This equation relates troponin’s binding of 
Ca++ to myosin’s ability to bind strongly to the thin filament. From previous work, we 
have estimated εmin to be 0.006 and εmax to be 0.5 (126). This equation is cleverly 
designed: if θ is near its maximum of 1, εmin goes to 1 while εmax goes to 0.5. Completing 
the equation results in ε = 0.5, suggesting that even in saturating Ca++, myosin only binds 
half as well to regulated actin as it does to unregulated actin. Conversely, when Ca++ is 
low, εmin goes to 0.006 while εmax goes to 1, so that completing the equation would result 
in ε = 0.006. Thus, myosin’s ability to bind to regulated actin can be mathematically 
modeled using the myosin binding rate to unregulated actin and θ, the fraction of 
Troponins bound with Ca++.  
We assume that Tn binding to Ca++ is fit by Michaelis-Menten and is determined 
by the equation:  
θ =  
[𝐶𝑎++]
𝐾 + [𝐶𝑎++]
 
Considering our assumptions, the only parameter that determines ε(Ca++) is K, TnC’s 
affinity to Ca++.  
In Vitro Motility Assay 
Background 
In the in vitro motility assay, a nitrocellulose-coated coverslip is secured to a glass 
microscope slide, creating a ‘flowcell’. Isolated myosin in solution is pipetted into the 
flowcell and adhered to the nitrocellulose. Fluorescent actin filaments are then flowed in, 
and the myosin on the surface can strongly bind to filaments (figure 3.6). When 
regulatory proteins are used, they are flowed in and allowed to incubate with the actin for 
seven minutes to ensure complete reconstitution of thin filaments (17, 57). Finally, the 
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motility buffer is added, with the appropriate pH and Ca++ conditions, as well as ATP to 
drive crossbridge cycling.  
The fluorescent filaments are visualized as myosin propels them across the 
surface. The filament movement can be observed and recorded, and the velocities can be 
determined by measuring the distance traveled and the frame rate of the recording 
camera.  
 
Figure 3.6. Cartoon of in vitro motility assay. Schematic of actin filaments (white) moving a surface of myosin 
molecules (orange). Figure courtesy of Mike Woodward. 
The hardware and software, proteins, solutions, and assay are all similar to or 
encompassed by those of the laser trap assay. What follows is a brief description of the 
assay with key differences from the laser trap assay discussed.  
Proteins 
All proteins used in the motility assay are exactly the same as described above.  
Solutions 
 Like the laser trap assay, myosin was ridded of dead heads and diluted, this time 
to 100 µg/mL for most experiments (the duty cycle requires a range from 5 to 100 
µg/mL). The final buffer was the same as before except 1% methylcellulose was added, a 
crowding agent that keeps filaments near the myosin-coated surface, and 2 mM ATP. On 
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the day of the experiment, actin was diluted to 10 nM as before, but this time in the 
absence the regulatory proteins, which was incorporated directly in the flowcell. The day 
of the experiment, troponin and tropomyosin was diluted to 0.75 μM and 0.25 μM, 
respectively, and mixed in AB with additional KCl. Further, 100 nm excess troponin and 
tropomyosin was added to the motility buffer to ensure complete regulation of the thin 
filaments (17, 57). For the large ensemble experiments, both ATP and Ca++ were 
manipulated in the motility buffer. For the pCa-velocity experiments comparing wild-
type and R146G troponin, the Ca++ was manipulated. For the ATP experiments, the ATP 
concentration was manipulated for both the wild-type and the R146G mutation.  
In Vitro Motility Assay 
 As before, myosin was added to the flowcell followed by BSA, which was 
allowed to incubate for one minute. After one minute, vortexed unlabeled actin is flowed 
in, which is another preventative measure against any ‘dead-head’ myosin. All myosin 
will bind to the unlabeled actin, but after ATP is added 30 seconds later, the live myosin 
will dissociate from the unlabeled actin. Additional ATP was added to ensure all live 
myosin have released the unlabeled actin. Labeled actin was then added and allowed to 
bind to the myosin for one minute. Labeled actin was again added, and incubated for 
another minute. The regulatory proteins were then added and allowed to incubate with the 
labeled actin for at least seven minutes. Finally, the motility buffer with the appropriate 
level of Ca++ and ATP was added.  
Hardware and Software 
Labeled actin velocity was visualized with an ICCD camera (XR/MEGA-10EX™ 
S30, Stanford Photonics Inc. Palo Alto, CA). This camera is attached to a Nikon Eclipse 
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Ti® inverted microscope with a 100x, oil-coupled, 1.4NA objective. Video frames were 
acquired through an Epix-LVDS frame grabber (Epix, Inc., Buffalo Grove, IL) and 
controlled using Piper Control™ software (Stanford Photonics, Inc. Palo Alto, CA). 
TRITC filters (Thor Labs, Newton, NJ) are incorporated into the optical path to excite 
and visualize the filament on the ICCD camera. The flowcell was maintained at 30°C 
with an objective temperature controller (20/20 Technologies Inc. Wilmington, NC). For 
each flowcell, three videos of different fields were recorded to get a sufficient sample of 
filament velocity, at 10 frames per second for 30 seconds. 
Regulated Thin Filament Velocity Analysis 
 Each video was analyzed using the ImageJ plugin WRMTRK, which skeletonizes 
each filament and determines distance traveled per unit time. This program tracks the 
filaments that fit the chosen parameters and output an average velocity for each field. Our 
parameters are as follows: to be considered moving, a filament must be at least 0.5 μm 
long and travel for at least three seconds. 
 Each experimental condition was performed at least three times. Each video 
typically captures 50-150 filaments. For the pCa-velocity measures, the data for each 
troponin variant was fit to the Hill equation to generate parameters (pCa50, Hill 
coefficient) for inferential statistics. Goodness-of-fit was determined with the R2 value. 
Significant differences in the Hill coefficient and the pCa50 were determined in a one-way 
ANOVA. For the duty cycle experiments, the data were fit to equation  
V = Vmax * (1 - (1 – f)N)  
where V is velocity, f is duty ratio, N is number of myosin heads (120). The major 
output, f, was statistically compared between the wild-type and R146G mutation by 
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comparing the value and the standard error to the fit. Similarly, the ATP experiments 
were fit to an exponential and the Km was statistically compared between the wild-type 
and R146G mutation by comparing the value and the standard error.  
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CHAPTER 4 
RESULTS 
We characterized thin filament regulation on the molecular level by directly 
observing single molecule interactions between myosin and a regulated thin filament in a 
three-bead laser trap assay. This is the first time, to our knowledge, that single myosin 
binding has been detected with a regulated thin filament in the three-bead laser trap 
assay. With a single myosin, our main measure was frequency of binding, which 
increased as Ca++ levels were increased. We then observed a small ensemble of myosin 
interact with a regulated thin filament and measured force, duration, and the time 
between events. The measurement of force, duration, and binding frequency of a small 
ensemble of myosin interacting with a regulated thin filament is a novel achievement and 
is a key step in bridging the gap in our understanding of single myosin kinetics to single 
fiber and whole muscle actions. Again, our measures were a function of Ca++, where 
force and duration increased and the time between events decreased as Ca++ was 
increased. Finally, we measured velocity as a function of Ca++ and ATP. In these 
experiments, high Ca++ produced velocities that follow a typical Michaelis-Menten 
relationship, while at low Ca++ there exists an ideal ATP level to initiate velocity and thus 
thin filament activation. In addition to our measures for thin filament activation, we 
tested the R146G Tn mutation in the in vitro motility assay. Our pCa-velocity results 
agree well with previous pCa-force and pCa-ATPase data, showing an increase in Ca++ 
sensitivity. We then teased out details of myosin’s kinetics, where the mutant was shown 
to reduce myosin’s duty cycle and reduce myosin’s ADP release rate.  
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Effect of Ca++ on Single Myosin Binding 
 We first tested the effect of Ca++ on thin filament activation by measuring the rate 
of binding between a single myosin and a regulated thin filament in the three-bead laser 
trap assay. At pCa 4, the binding rate was 0.85 events per second, and this rate slightly 
increased to 1.11 at pCa 5, but then dropped to 0.45 at pCa 6 and then 0.23 at pCa 7 
(table 1). Binding events were not detected at pCa 9, despite over 100 recordings totaling 
more than 9 minutes. Therefore, we have included a value for pCa 9 published previously 
for comparative purposes (62). These data are summarized in table 1. Sample traces show 
either many events (pCa 4) or very few events (pCa 7) depending on the Ca++ 
concentration (figure 4.1). The rates achieved at pCa 4 and 5 are about half of rates 
achieved with an unregulated thin filament (2.2 events per second), in agreement with 
other work that has examined single molecules interacting with a regulated thin filament 
(29).  
 In our experimental set up, placing the thin filament above the 3 µm mogul so that 
myosin can bind is crucial. If the filament is too high in the experimental chamber, 
myosin will not be able to reach the filament. To be sure that our low binding frequency 
at low Ca++ was not simply due to this experimental error, we measured the height of the 
actin filament under different Ca++ concentrations. This was done by taking an image of 
the 3 µm bead and using the airy disk to determine height. We found that the height 
across conditions was not significantly different (figure 4.2). We also found that the step 
size and attachment time of binding events were not significantly different across pCa 
levels (figure 4.3 and 4.4) 
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Effect of Ca++ on Binding of a Small Ensemble of Myosin  
 We then tested the effect of Ca++ on the ability of a small ensemble of myosin to 
bind to and generate force against a regulated thin filament in the three-bead laser trap 
assay. These experiments could shed light upon cooperativity in muscle, where one 
myosin’s binding to actin increases the probability of a nearby myosin binding. Based on 
our myosin concentration and estimates of myosin availability, we suspect 6 to 8 myosin 
heads were available to bind to the regulated thin filament (27). Hundreds of events were 
recorded and plotted in a histogram (figure 4.5). At pCa 5, a wide distribution of forces 
was generated, from 0.2 to 10.8 pN, suggesting that an event can be composed of either a 
single head binding and releasing, multiple heads binding and then releasing, or multiple 
heads binding, cycling multiple times, and then releasing. As the Ca++ was reduced to 
pCa 6, 6.5, and 7 the peak forces decreased to 9.4, 5.0, and 2.8 pN, respectively. An 
analysis of the data using the non-parametric Kruskall-Wallis ANOVA followed by 
Dunn’s post hoc tests found no significant difference between pCa 5 and pCa 6, but did 
see a difference between pCa 6 and pCa 6.5 as well as pCa 7. The comparisons are 
summarized in table 4.2. The duration of events also had a broad distribution and 
decreased with reduced Ca++ levels, coinciding with the force values (figure 4.6). Indeed, 
the relationship between force and event duration form a linear relationship (figure 4.7).  
 In addition to measuring force and duration of each event, we also measured the 
time between events (figure 4.8). This information provides insight into the strong 
binding of the first myosin molecule. We prefer the measure of time between events over 
binding frequency with the small ensemble data. This is because an “event” with small 
myosin ensembles can include many actomyosin interactions, especially those events that 
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produce large forces. Therefore, the time between events can provide insight into the rate 
of binding of the first myosin molecule at the start of any event, regardless of the event’s 
peak force and duration. At pCa 5 the distribution of time between events was dominated 
by short times: approximately half of the time another event occurs within 100 ms. As the 
Ca++ is reduced, this percentage drops, and at pCa 7 often more than a second would pass 
before another event occurred. As the Ca++ was reduced to pCa 9, events became very 
infrequent, where the time between events was often 5 seconds or more. We were able to 
use the event duration data with the time between events data to calculate the percentage 
of time where at least one myosin head was strongly bound. At pCa 5, this value was 
31%, but it decreased to 10% and 2% at pCa 6 and 7, respectively.  
Effect of Ca++ and ATP on Binding of a Large Ensemble of Myosin  
 Finally, we performed the in vitro motility assay with regulated thin filaments and 
measured velocity as a function of Ca++ and ATP (figure 4.9). This method can provide 
insight into the importance and role of Ca++ and myosin in thin filament activation. At 
ATP levels <60 µM, the filaments were motile and the velocity was not different across 
pCa levels. The most logical explanation for velocity at low ATP is thin filament 
activation through myosin rigor binding. One myosin binding pushes the tropomyosin 
into open state, revealing additional myosin binding sites on actin nearby. The activation 
here is slightly different than that which occurs under physiological conditions because 
the ATP is low. Because the ATP concentration is low, the initial myosin binding event 
lasts a considerable amount of time, providing ample time for nearby myosin molecules 
to bind to the regulated thin filament. Thus, rigor activation occurs at an ATP 
concentration where heads are bound long enough to enable nearby myosins to bind, but 
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short enough to allow processive movement. As the ATP was increased, however, the 
velocities diverged in a Ca++ dependent manner. For example, at pCa 9, filaments ceased 
to move, but at pCa 4 the filaments approached maximum velocity. The peak velocity for 
each pCa level was widely distributed, with the largest difference between successive 
Ca++ concentrations existing between pCa 6.5 and pCa 7.  
Mathematical Model 
 The mathematical model can be used to determine TnC’s affinity for Ca++ in all 
three experiments (single molecule, small ensemble, large ensemble). We can also test 
the model to determine if a coupling distance of 400 nm is appropriate. The single 
molecule experiments don’t have coupling, and therefore provide a clear picture of the 
role of Ca++ on myosin’s weak to strong transition rate. The rates we observed were very 
low (~1 event per second) compared to the transition rate observed in solution (~40/s) 
(68, 94). This is most likely due to fluctuations in the thin filaments position relative the 
single myosin molecules and not an effect on the myosin’s kinetics per se. When 
correcting for this, the data are well fit by our model (figure 4.10) (see equations in 
Methods: Mathematical Model), and generate a value for K of 0.216 ± 0.055 µM.  
 The small ensemble experiments have both Ca++ and myosin strong binding 
activation. Here, we can use the model to separate the effects of these two activators, as 
well as test the model’s assumption of a local coupling distance of 400 nm. To do this, 
we simulated data to match the raw the data. The model was able to reasonably replicate 
the data (figure 4.11). We varied K to in the model to best replicate the raw data. This 
resulted in K = 0.199 ± 0.044 µM. This lines up well with our previous estimate of K = 
0.216 ± 0.055 from the single molecule data.  
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 To further test the model, we collected data with large ensembles with motility 
experiments. This leads to strong local coupling, as the concentration of myosin was 100 
µg/mL. In such conditions, myosin can activate the thin filament through strong binding, 
even at low Ca++. This is achieved by reducing the ATP levels and thus prolonging the 
strongly bound rigor state of myosin. Such conditions allow one strongly bound myosin 
to push tropomyosin, allowing neighboring myosin to strongly bind as well. In the 
absence of Ca++, we found that rigor myosin were able to activate the thin filament and 
increase velocity as a function of ATP. We found that for low Ca++ conditions (pCa 9), 
60 µM ATP was a critical point, where velocity decreased as ATP was increased beyond 
60 µM. This agrees well with previous data (62). We tested the role of strong binding 
activation by repeating these experiments with different Ca++ concentrations. We found 
that 60 µM was a critical point for many other Ca++ concentrations. We used the model to 
match the experimental data (figure 4.12). We determined values of ε to optimize the fit 
of the data. The data were well fit by equations (1) and (2), and generated a value for K = 
0.217 ± 0.034 µM. 
The estimate of ε along with the fits are surprisingly similar to the fits generated 
for the single molecule and small ensemble data. The model is able to explain thin 
filament activation across many levels, and is able to tease apart the role of Ca++ and 
myosin strong binding on thin filament activation.  
R146G Mutation 
 In addition to examining thin filament activation with wild type regulatory 
proteins, we examined the effect of a cardiomyopathy-inducing mutated troponin. This 
particular mutation has proven to be a difficult to understand due to the lack of consensus 
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of the mutation’s effect as well as the odd result that the mutation seems to not only 
affect myosin’s on-rate but also other steps of the crossbridge cycle (we expect troponin 
to affect myosin’s weak to strong transition, but not other steps such as ADP release or 
ATP binding). To address this, we measured the velocity of regulated thin filaments in 
the in vitro motility assay either in the presence or absence of the mutant. 
The Effect of the R146G Mutation on pCa-Velocity 
 Our first test was to examine the mutant’s effect on the pCa-velocity relationship 
(figure 4.13). Under high Ca++ concentrations, the filaments with the R146G mutation are 
moving but are significantly slower than filaments with wild-type troponin. However, 
under low Ca++ conditions, filaments with the mutation move significantly faster than 
wild-type. Similar findings have been found with force measurements in muscle fibers 
(69, 70, 114, 129). The reduced velocity under high Ca++ conditions and the relative 
increase in velocity under low Ca++ conditions may explain the data’s poor fit to the Hill 
equation. The wild type is well fit with the Hill equation (R2 = 0.97), however, the mutant 
is poorly fit (R2 = 0.31). The results also show a leftward shift in the curve and a 
subsequent increase in the pCa50, suggesting earlier activation with the mutation. This 
result is in agreement with many (12, 34, 70, 114, 129), but not all (69), of the previous 
studies examining this mutation’s effect on Ca++ sensitivity in force and ATPase 
measurements.  
The Effect of the R146 Mutation on duty cycle 
 To identify the mechanism of the R146G mutation, we measured the velocity of 
thin filaments in a duty cycle motility assay. In this motility assay, the myosin 
concentration is manipulated and the resulting velocities are fit to the duty cycle equation 
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(see Methods: Regulated Thin Filament Velocity Analysis) (120).  This assay gives an 
estimate of the percentage of myosin heads bound to the regulated thin filament at any 
given moment. The increase in the pCa50 suggest that the mutant would increase the duty 
cycle, however, our results show a slight decrease in duty cycle in the presence of the 
mutation, from 1.81% to 1.39% (figure 4.14). Our results also showed a reduced velocity, 
even at maximum myosin concentration, from 4.63 ± 0.15 µm/s with the wild-type to 
2.49 ± 0.11 µm/s with the mutant. To be sure that this didn’t affect our duty cycle result, 
we normalized the duty cycle results; this however, did not change the outcome. A 
possible explanation for the pCa-velocity and duty cycle results is that the R146 mutant 
slows ADP release, leading to slower maximal velocities but higher velocity at low Ca++, 
in addition to dramatically reducing myosin’s on-rate. If the on-rate is slowed 
significantly more than the ADP release rate, the overall effect would be a reduction in 
the duty cycle, as we observed.  
The effect of the R146G Mutation on ADP release 
 To further explore the effect of the mutant on myosin’s kinetics, we measured 
regulated thin filament velocity as a function of ATP concertation (figure 4.16). These 
data were fit to a Michaelis-Menten relationship and the parameters are shown in Table 
4.3. Again, the maximum velocity was reduced in the presence of mutation relative to the 
wild type, decreasing from 4.54 ± 0.13 µm/s to 2.56 ± 0.06 µm/s. To examine ADP 
release rate, the data was converted to time on (ton), which is the displacement generated 
by 1 myosin head, assumed to be 10 nm (d=10 nm), divided by the velocity of the thin 
filament (ton = d / V). The ton data can then be used to estimate ADP lifetime and rigor 
lifetime, assuming that ton is made up entirely of ADP lifetime at saturating ATP and that 
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ton = the time of the ADP lifetime plus the time of rigor where myosin is waiting for ATP 
to induce actomyosin dissociation (ton = t-ADP + trigor). Our results show a reduction in the 
ADP release rate in the presence of the mutation (figure 4.17, table 4.3), decreasing from 
401.3 s-1 with the wild type to 248.4 s-1 with the mutant.  
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CHAPTER 5 
DISCUSSION 
With our first set of experiments, we were able to examine thin filament 
activation and tease apart the role of Ca++ and myosin strong binding. Our first set of 
experiments give us a better understanding of thin filament activation under normal 
conditions, and we hope to use this knowledge to examine perturbations, such as acute 
changes in metabolites or chronic mutations in key muscle proteins. In our second set of 
experiments, we examined a specific mutation in troponin that is associated with 
cardiomyopathy.  
Thin Filament Activation 
 According to the 3-state model (81), thin filament activation requires both Ca++ 
binding to Tn as well as myosin strong binding to the thin filament. However, the role 
that each of these play in activation are unclear. Some have suggested that strong binding 
doesn’t play a crucial role under physiological ATP levels (41). Others have suggested 
that myosin’s weak to strong binding transition is Ca++ independent (16). To better 
understand the significance of each mechanism, we directly observed single molecules, 
small ensembles, and large ensembles of myosin bind to actin under a spectrum of Ca++ 
concentrations. This is the first time, to our knowledge, that force and motion of single 
and small ensembles of myosin have been directly observed under such a wide range of 
Ca++ concentrations. Such experiments give us a bottom-up view of thin filament 
activation and can help us tease apart the role of Ca++ and strong myosin binding. 
Single Molecule Binding 
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 Single myosin binding to a single thin filament was observed in the laser trap at 
various Ca++ levels. As Ca++ is reduced, binding events became less frequent, declining 
from 0.85/s at pCa 4 down to 0.02/s at pCa 9. This data agrees with models that suggest 
Ca++ affects myosin’s weak to strong binding transition and disagrees with models that 
suggest Ca++ alters other kinetic steps, such as phosphate release (16). Our data and 
model do also do not support the notion that Ca++ has an allosteric effect on the thin 
filament which controls myosin binding (16, 53, 117).  
 Even at saturating Ca++, the binding frequency was only 0.85/s, more than half the 
binding frequency observed with an unregulated actin filament (2.2/s). Similar findings 
have been obtained in a landing assay, where the ability of S1 myosin to land on a Ca++-
activated thin filament was reduced compared to an unregulated actin filament (29). 
Mathematical models have included this, suggesting that there is still an energy barrier 
that myosin must overcome, even at saturating Ca++ (126, 127). Solution experiments 
have also shown that ATPase is inhibited at low S1 myosin concentrations in the 
presence of regulatory proteins and saturating Ca++ (72). 
 Under the conditions of the laser trap, the thin filament is placed close to the top 
of the 3 µm myosin-coated mogul. In this experiment, the height is crucial: filament 
heights above 3.5 µm or below 3.0 will result in either no binding or unproductive 
binding between either actin and myosin or actin and the surface of the mogul. 
Differences in height across Ca++ concentrations could lead confounding results. To 
ensure our single molecule binding was indeed Ca++ dependent and not due to 
experimental error in height, an image of the mogul was captured during data collection 
and analyzed after the experiment. Any recordings collected out of our range of 3.0 to 3.5 
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µm was disregarded. We found that the height of the thin filament was not significantly 
different from pCa 4 to pCa 9 (figure 4.2) 
Myosin Ensembles 
 Our single molecule binding frequency data could be fit to a pCa curve. Though 
the fit is good (figure 4.10), the Hill coefficient is low (1.4 ± 0.3)This does not agree well 
with pCa-force curves, which can show Hill coefficients up to 6 (9). Our low Hill 
coefficient confirms that some cooperativity exists even in the absence of multiple 
myosin. Cooperativity can occur in four main ways: 1) coupling between the two Ca++ 
binding sites on fast skeletal TnC, 2) coupling between Ca++ binding sites down the thin 
filament, 3) myosin strong binding inducing Ca++ binding to TnC, and 4) myosin strong 
binding inducing movement of tropomyosin into an open state so other myosin can more 
easily bind (44). The first two mechanisms may play a role, but can only produce Hill 
coefficients up to 1.2 or 1.5, respectively (46). Though these mechanisms contribute, they 
do not seem to be the main mechanism(s) of the cooperativity observed in thin filament 
activation. Mechanism (4), where myosin strong binding induces other neighboring 
myosins to strongly bind, could play a larger role than other mechanisms. Indeed, the 
importance of strong myosin binding has been demonstrated with NEM myosin, which 
strongly bind to actin but do not release. Experiments have shown that rigor or NEM 
myosin are capable of activating a thin filament (49, 111). Experiments with fluorescent 
probes in fibers (112) have compared the overlap region to the nonoverlap region and 
showed that endogenous myosin binding leads to S1 binding in the overlap region, but 
not in the nonoverlap region. Though many examples exist to demonstrate strong-binding 
cooperativity, some question the physiological relevance of this mechanism (41). This 
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concern is valid, as these previous experiments were done at very low ATP, much lower 
than physiological levels. Recent work has shown that Tn and Tm dynamics are much 
faster than myosin kinetics, suggesting that myosin strong binding would not play a large 
role in activation (41).  
By using a small ensemble of myosin in the laser trap at 100 µM ATP, we could 
examine the role of myosin strong binding under near-physiological conditions. This 
ATP concentration is up to 1,000x typical myosin strong binding experiments. Further, 
with this ATP concentration, we would expect short but detectable (10 ms) binding 
durations per each myosin. At high Ca++, the myosin ensembles produced a wide 
distribution of forces. Interestingly, most of the events produces low force (1-2 pN), 
though some binding events went as high as 11 pN. As Ca++ was reduced, these larger 
forces disappeared. For example, the highest force produced at pCa 7 was 3 pN, and pCa 
9 produced events that looked like single molecule events.  
To further examine the role of Ca++ and strong binding myosin in activating the 
thin filament, we performed motility experiments while manipulating Ca++ and ATP. 
Previous work has shown that at high Ca++, motility velocities are well described by a 
Michaelis-Menten relationship as ATP is increased. However, at low Ca++, velocity rises 
up until ~60 µM ATP, and then slowly declines (62). We build off of this previous work 
by examining the effect of a wide range of Ca++ levels, from pCa 9 to pCa 4. Our data 
confirm that 60 µM is a critical ATP concentration.  
Mathematical Model 
To separate the effects of Ca++ and myosin strong binding, we compared our data 
to a mathematical model. The model was able to replicate the experimental data well at 
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all levels (single molecule, small ensemble, large ensemble). Impressively, the model 
generated values for the Tn- Ca++ binding affinity that are extremely similar across all 
three levels. In addition, the model was able to tease apart the role of Ca++ and myosin 
strong binding. Using the model, we were able to extrapolate force generation as if each 
myosin molecule acted independently (i.e., no myosin strong binding activation or 
cooperativity. The resulting pCa-force curve had a low Hill coefficient (1.4 ± 0.3) and 
low pCa50 value (5.96). Even if we 
tried to shift the curve to line up 
with pCa-force data collected in 
fibers, the curve is still not steep 
enough to match these data. 
However, once myosin strong 
binding activation is added into the 
model, the model is able to 
recapitulate a typical pCa-force 
curve. The model recapitulates data generated from single muscle fibers (85), with a Hill 
efficient of 1.7 ± 0.2 and a pCa50 of 6.81 (figure 5.1). Therefore, myosin strong binding 
activation is necessary to describe experimental data.  
The model predicts myosin are locally coupled if they are within 400 nm of each 
other. In the model, if two strongly bound myosin are within this range, then the thin 
filament is activated between the two myosins. Further, if one myosin is strongly bound, 
the probability of a neighboring myosin also binding is increased. This probability is 
affected by how close the second myosin is: the closer the second myosin is to the first 
Figure 5.1. pCa-force relationship for single molecule data and 
our model. We fit our single molecule binding data to a pCa 
curve. This curve is shallow and shifted to the right compared 
to pCa-force data from fibers. The model incorporates 
cooperativity, and can therefore duplicate experimental data 
with an appropriate Hill coefficient and pCa50.  
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myosin, the higher the increase in probability of the second myosin binding.  An 
important note is that this length of 
400 nm (ℓ) is not the same as the 
cooperative unit length (µ), as ℓ 
implies only partial activation. In 
other words, an increase in the 
attachment rate would be 
miniscule 400 nm from the point 
of first attachment because the 
function drops off rapidly away 
from the site of first attachment. 
Assuming tropomyosin is a 
flexible chain, we feel that ℓ better 
captures the effect of strongly bound myosin, and the model better encapsulates myosin 
strong binding activation compared to models that use the cooperative unit. Further, the 
cooperative unit length has been hard to determine, with ranges from 40 nm to 500 nm 
(62, 74, 77, 80, 97, 103, 122). Meanwhile, ℓ has been determined to be 400 nm. Indeed, 
previous experiments have led to this conclusion (127), and our current results support 
this distance. In fact, for the model to fit our data, a coupling length of 400 ± 100 nm was 
not only sufficient but necessary. Thus, our data confirm the model’s prediction of the 
coupling length between myosin, regardless of the number of myosin present.  
Based on the myosin concentration used and the geometry of the experimental 
setup (in particular, the use of a 3 µm bead as a pedestal for myosin), we expect ~7 
Figure 5.2. Depiction of the mathematical model. Top: two 
myosin activate the region between them (red). Regions with only 
one myosin bound (white) lead to partial activation for a distance. 
Middle: model of tropomyosin’s position, depending on myosin 
strong binding. Bottom: probability (ka) of neighboring myosin 
binding.  
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myosin molecules could interact with the thin filament (27, 51). The mathematical model 
we used suggests that 14-22 myosin were available. We attempted to reconcile this 
difference by using TIRF to quantify the number of myosin in a given area, and compare 
this value to the area on the 3 µm pedestal that would provide myosin the ability to bind 
to thin filament. Unfortunately, there was much variability in this experiment. Regardless 
of the exact number of myosin, the myosin molecules would have had to at least 
communicate over a distance of 36 nm. This assumes that the 3 µm pedestal bead 
provides a ~500 nm region where myosin can reach the thin filament. If 14 myosin were 
evenly spaced out on this 500 nm region, they would be 36 nm apart, on average. If the 
number of myosin was closer to 7, they would be 71 nm apart, on average. Thus, 
cooperativity observed in our experiments is likely not due to cooperative binding of 
myosin within a regulatory unit, but rather due to cooperative binding of myosin beyond 
their own regulatory unit. This concept is confirmed by our data, as the local coupling 
length in the model is 400 nm. 
Limitations 
The performed experiments do not go without limitations. Future experiments can 
provide more detail into the molecular mechanisms of thin filament activation with 
improvements on the current experiments. The first limitation is the use of 100 µM ATP. 
We chose this concentration because it allows us to detect many binding events. Higher 
concentrations could lead to events that occur so quickly that our system would not detect 
it (>5 ms). On the other hand, we wanted to ensure that myosin was in the form of 
ADP.Pi, and not ADP or rigor. We are confident, based on the ATP binding constant of 
myosin, that we achieved our goal.  
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The second limitation is the random configuration of myosin on the 3 µm mogul. 
To better recapitulate muscle in vivo, future experiments could use reconstituted thick 
filaments. Such filaments can be designed to not only duplicate the spacing of myosin in 
vivo, but could also be manipulated to add extra myosin or take myosin away. A nice 
feature would be the ability to count the myosin interacting with the actin filament. This 
could be done possibly by dual color microscopy, where the actin and myosin are labeled 
with different color fluorophores.  
The third limitation is the shape of the 3 µm mogul. The curved surface of the 3 
µm mogul leads to particular phenomena, such as different binding rates of the first and 
second myosin during a small ensemble run. Future experiments could examine a flat 
pedestal instead of round one. Maybe even more important is the ability to control the 
thin filament in the Z-axis. Current microscopes provide feedback to maintain the height 
of the experimental set up, but many do not have nm resolution.  
R146G Mutation 
  
 Of the three subunits of troponin, the inhibitory region, TnI, is responsible for 
binding to actin in the absence of Ca++ and subsequently keeping tropomyosin in the 
blocked state. Upon Ca++ binding, TnI detaches from actin and binds to TnC, allowing 
tropomyosin to move freely over the actin surface. A key part of TnI’s function is the 
inhibitory region, which spans residues 96-116 on skeletal TnI and 126-146 on cardiac 
TnI, and is responsible for binding to actin in the absence of Ca++. This places our 
mutation of interest, R146G, just within this key inhibitory region.  
 The data for this mutant are equivocal for many measurements. Some have found 
that force is reduced in the presence of the mutant at maximal Ca++ (70, 129), but others 
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have not seen this (114, 132). Similarly, some have found that ATPase is reduced (70, 
114), but others have not seen this (34, 129), and some have seen that velocity is reduced 
in motility (12), but not in fibers (60). The results make it difficult to say clearly if this 
mutant has an effect at all on peak force, ATPase, or velocity. However, most work 
agrees that there is a shift in the pCa50 across ATPase, force, and velocity measures (12, 
60, 70, 114, 129, 132). 
 We have collected data in agreement with previous findings. Under maximal Ca++ 
conditions, we see a ~46% reduction in velocity. We also see a leftward shift in the pCa-
velocity relationship. To try to tease apart the mechanism behind this, we examined the 
ADP release rate and the duty ratio. We found that the duty ratio decreased ~22%, from 
1.8 to 1.4%. In separate experiments, we found that the ADP release rate was reduced by 
~38%. What follows is set of possible explanation for these phenomena.  
 The observed decrease in velocity, even in the presence of maximal Ca++, is in 
agreement with previous findings. The reduced velocity can happen if myosin’s kinetics 
are altered. One of myosin’s kinetic steps that may be slowed is the weak to strong 
transition. This is the step that the regulatory proteins control, and the R146G mutant may 
impede myosin’s weak to strong transition more than the wild-type Tn. Previous data (29, 
126, 127) and our data presented here suggest that the weak to strong transition rate is 
reduced in the presence of regulatory proteins, even at maximal Ca++. The mutant may 
exacerbate this reduction. The structural mechanism could be that the mutant TnI, rather 
than binding to TnC at maximal Ca++, stays attached to actin, keeping tropomyosin in the 
blocked state. Some of the TnI molecules may come off of actin, but a high enough 
percentage may stay bound to actin, preventing complete thin filament activation. To test 
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whether the myosin’s weak to strong transition was limited, we performed duty cycle 
experiments. In these experiments, velocity is measured as a function of myosin 
concentration. The data can be fit to the duty cycle equation to determine the percentage 
of myosin molecules bound at any given time. The presence of the mutant induced a 
reduction in the duty cycle from 1.8 to 1.4%. These duty cycles are relatively low 
compared to previous measures, but a relative comparison would imply that myosin 
spend less time on actin in the presence of the mutant. This could be due to a reduction in 
the weak to strong transition rate.  
 Alternatively, the reduction in velocity could be due to a reduced ADP release 
rate. Our duty cycle experiments would suggest that this step is not the culprit, as a 
reduced ADP release rate would prolong myosin’s time attached to actin and thus 
increase the duty ratio. This would be in disagreement with our findings. To be sure, we 
completed experiments to calculate the ADP release rate by measuring velocity as a 
funciton of ATP. We assume that the mutant does not affect the ATP binding constant of 
rigor myosin. When we fit these velocity-ATP data, we found that the ADP release rate 
was indeed reduced in the presence of the mutant. Based on the duty cycle experiments, 
the reduction in ADP release rate was not expected but is still possible: both the weak to 
strong transition rate and the ADP release rate may be slowed, but the former is slowed to 
a greater extent than the latter. This would lead to reduced velocity as well as a reduced 
duty cycle.  
 How the weak to strong transition could be altered by a Tn mutant may be easy to 
explain, how the Tn mutant would alter ADP release is unclear. The Tn mutant may 
interact with myosin and can alter its kinetics. Though this is possible based on the 
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proximity of myosin to the regulatory proteins, this Tn-myosin interaction seems 
unlikely, considering TnI can only reach two of the seven actin monomers in a regulatory 
unit, and would thus only be able to affect myosin if the myosin was bound to those actin 
monomers. Recent investigations have made progress in examining the interactions of 
myosin-thin filament residues using cryo-EM (124, 125), but currently lack the ability to 
characterize the loose C-terminal of TnI. 
 To further complicate matters, we found, in agreement with previous work, that 
the mutant induces a leftward shift in the pCa-velocity relationship. This would seem to 
complicate the story, as a leftward shift isn’t expected when myosin’s on-rate is slowed. 
However, a reduced ADP release rate may contribute to strong binding activation. The 
longer myosin stays bound to actin, the higher the probability of a neighboring myosin 
binding as well.   
 The pCa-velocity relationship in the presence of the mutant is not fit well 
(R=.307). Indeed, the difference in velocity between low Ca++ and high Ca++ is only 1 
µm/s. It seems that the mutant isn’t very sensitive to Ca++ at all. Others have shown that 
peak velocity or ATPase is reduced at maximal Ca++ compared to wild type, yet the thin 
filaments with the mutant are not able to completely inhibit ATPase activity. Assuming a 
three-state model of regulation, the vast majority (~99%) of myosin binding sites on actin 
should be blocked. However, the R146G mutation may limit TnI’s ability to bind to actin, 
allowing tropomyosin to move freely around the closed state and increasing myosin’s 
probability of binding to actin. Conversely, the mutated TnI may not bind to TnC as well 
as the wild-type during maximal Ca++ activation. Thus, thin filaments in the presence of 
the R146G mutation fluctuate between blocked, closed and open, regardless of Ca++, and 
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the distribution of these three states is not strongly dependent on Ca++ compared to wild-
type proteins. Others have confirmed this idea, suggesting that the R146G mutant 
stabilizes the closed position (61). Determining the precise distribution of open, closed, 
and blocked from our data is not possible, but future work examining single molecule and 
small ensembles in the laser trap, along with mathematical modeling, could provide 
insight.  
 Future work could examine how this mutant (and other mutants) affect single 
myosin molecule binding as well as other kinetic steps. This can be done using the laser 
trap assay. Our current findings suggest that both the weak to strong transition as well as 
ADP release are slowed in the presence of R146G. A single molecule laser trap assay 
would be able to directly observe this behavior. It would then be possible to examine how 
this single molecule behavior affects a small ensemble of myosin in producing force and 
motion. Further, these measures can be examined over a range of Ca++ concentrations, 
which would provide insight into the leftward shift in the pCa-velocity relationship.  
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TABLES AND FIGURES 
 
 
Table 4.1: Events per Second for Single 
Molecule Binding Events 
pCa Events per Second 
4 0.85 
5 1.11 
6 0.45 
7 0.23 
  9* 0.01 
*pCa 9 was published by Kad 2005 (62) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3: Fit parameters for R146G data  
Measure WT R146G 
Vmax (µm/s) 4.54 ± 0.13 2.56 ± 0.06* 
Km (µM) 264 ± 33 132 ± 17 
ADP Lifetime (s) 0.0024 0.0040* 
ADP Release Rate (s-1) 410.29 248.37* 
 
 
 
 
 
Table 4.2: Significant Differences of Ensemble Forces 
between Ca++ Concentration 
  Comparison   
Significant 
Difference 
    
pCa 5 vs. pCa 6 No 
pCa 5 vs. 
pCa 
6.5 Yes 
pCa 5 vs. pCa 7 Yes 
pCa 6 vs. 
pCa 
6.5  Yes 
pCa 6 vs. pCa 7 Yes 
pCa 6.5  vs. pCa 7 Yes 
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Figure 4.1. Sample traces of single molecule binding events at pCa 4 (left) and pCa 7 (right). Single 
molecule binding events became less frequent as Ca++ was reduced. 
 
 
 
 
Figure 4.2. Height of a regulated thin filament in the single molecule laser trap assay. The height of the RTF 
was not significantly different from pCa 4 to pCa 9. 
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Figure 4.3. Step size in single molecule experiments. The step size was not significantly different across 
pCa levels. 
 
 
Figure 4.4. Attachment time during single molecule experiments. The attachment time was not significantly 
different across pCa levels. 
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Figure 4.5. Force Histograms for each pCa. Events were most frequent and most likely to produce 
high forces at pCa 5. Event frequency and peak force declined as Ca++ was reduced. Events were 
extremely rare at pCa 9, as shown by the inset.  
 
 
 
 
 
Figure 4.6. Histogram of Event Duration for each pCa. At pCa 5, events lasted for hundreds of 
milliseconds, but duration declined as Ca++ was reduced. Despite the high myosin concentration, 
events at pCa 9 typically lasted less than 15 ms.  
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Figure 4.7. Relationship between Force and Duration at pCa5. As the myosin ensemble generated force, the 
event duration was prolonged. 
 
 
Figure 4.8. Time between events at each pCa. At pCa 5, events occurred in repid succession. However, as 
Ca++ was reduced, events became less frequent. At pCa 9, the time between events was many seconds.  
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Figure 4.9. Velocity of regulated thin filaments as a function of Ca++ and ATP in an in vitro motility assay. At 
pCa 4, velocity follows a typical Michaelis Menten relationship. However, at pCa 9, there exists an ideal ATP 
level to generate maximum velocity. The velocity depends not only on actomyosin binding sites availability, 
which is partially dictated by Ca++, and myosin on-time, which is dictated by ATP binding. 
 
 
Figure 4.10. Comparing our single molecule data to the mathematical model. The single molecule binding 
rate directly measured was well fit by the mathematical model. 
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Figure 4.11. Comparing our small ensemble data to the model. The force and on-time were converted to a 
relative frequency (gray bars) and are well fit by the mathematical model (red line). 
 
 
 
 
 
 
Figure 4.12. Comparing our large ensemble data to the model. The thin filament speed is well fit by the 
model, regardless of ATP and Ca++. 
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Figure 4.13. pCa-Velocity relationship generated in an in vitro motility assay. Wild-type (black) produced a 
typical sigmoidal curve, while the mutant (white) was poorly fit to the Hill equation due to low velocity at 
maximum Ca++ and elevated velocity at low Ca++. 
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Figure 4.14. Velocity as a function of available myosin heads in an in vitro motility assay. Also known as a 
duty cycle assay, the myosin concentration was manipulated and number of heads available was estimated 
using the data in Harris and Warshaw 1993 (51). The duty cycle was slightly lower with the mutant (1.39%, 
white) while the wild-type (black) was 1.81%. 
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Figure 4.15. Same data as Figure 4.9, but shown here normalized to each Tn variant's peak velocity. This 
better shows how similar the duty cycle is between each condition. 
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Figure 4.16. Velocity of each Tn variant as a function of ATP. By measuring velocity as a function of ATP, 
we can calculate the ADP release rate (table 4.3) 
 
 
Figure 4.17. Using the same data in figure 4.11, we can calculate time on by measuring velocity and by 
assuming that myosin displaces actin 10 nm with each powerstroke. 
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